AIMX:COIL ESEF Annual Report
Coiled Therapeutics PLC (AIMX:COIL)
ESEF Annual Report
2023-06-05
For: 2022-12-31
View Original
Added on
October 02, 2026
Roquefort Therapeutics plc
85 Great Portland Street
First Floor
London W1W 7LT
www.roquefortplc.com
Annual Report & Financial Statements
for the year ended 31 December 2022
Company Registration No. 12819145 (England and Wales)
Contents
Page
Corporate Information 2
Chairman’s Statement 3
Board of Directors and Senior Management 6
Directors’ Report 9
Strategic Report 13
Governance Report 23
Remuneration Committee Report 27
Audit Committee Report 33
Nomination Committee Report 35
Independent Auditors’ Report 36
Consolidated Statement of Comprehensive Income 46
Consolidated Statement of Financial Position 47
Statement of Financial Position 48
Consolidated Statement of Changes in Equity 49
Statement of Changes in Equity 50
Consolidated Statement of Cash Flow 51
Statement of Cash Flow 52
Notes to the Financial Statements 53
Annual Report & Financial Statements 2022 1
Corporate Information
Directors
Stephen West
Trevor Ajanthan (Ajan) Reginald (appointed 16 September 2022)
Prof. Sir Martin Evans (appointed 16 September 2022)
Dr Darrin Disley (appointed 16 September 2022)
Ms Jean Duvall (appointed 5 April 2022)
Dr Simon Sinclair (appointed 20 April 2022)
Dr Michael Stein
Mark Freeman (resigned 16 September 2022)
Mark Rollins (resigned 4 April 2022)
Company Secretary
Orana Corporate LLP
Registered Office
85 Great Portland Street
First Floor
London W1W 7LT
Registered Number
12819145
Joint Brokers
Hybridan LLP Optiva Securities Limited
1 Poultry 118 Piccadilly
London EC2R 8EJ London W1J 7NW
Independent Auditor
BDO LLP
Level 12, Thames Tower
Station Road
Reading RG1 1LX
Solicitors
Axiom Ince Limited
Aldgate Tower, 2 Leman Street
London E1 8QN
Principal Bankers
Alpha FX
2 Eastbourne Terrace
London W2 6LG
Registrars
Share Registrars Limited
27/28 Endcastle Street
London W1W 8DH
2 Roquefort Therapeutics plc
Annual Report & Financial Statements 2022 3
Chairman’s Statement
I am pleased to report the audited financial statements to shareholders for the year ended 31 December 2022.
During the year Roquefort Therapeutics (the “Company” and together with its subsidiaries, the “Group”) has made
substantial progress towards its corporate goals.
Most notably, in September 2022, Roquefort Therapeutics successfully completed a fundraise via the issue of
7,249,998 ordinary shares raising total gross cash proceeds of £1,015,000 and the acquisition of Oncogeni for an
aggregate equity consideration fair value of £3.75 million through the issue of 50,000,000 new ordinary shares in
the Company (the “Acquisition”), transforming Roquefort Therapeutics into a material oncology Group.
Roquefort Therapeutics completed the integration of the Oncogeni portfolio and enhanced the Group’s network
of partnerships with leading academic cancer research centres. These partners complement the Group’s own
world-class in-house expertise and laboratory infrastructure and enable Roquefort Therapeutics to implement a
broader and more effective development strategy. The Group believes its distributed R&D model is highly scalable
and cost effective.
In parallel, business development activities were significantly enhanced by meeting a number of leading
pharmaceutical companies to introduce Roquefort Therapeutics and present the novel portfolio. This has enabled
the Group to accelerate the out-licensing strategy in both core and non-core applications.
Acquisition of Oncogeni
The acquisition of Oncogeni, diversified Roquefort Therapeutics into a material oncology group with a pre-clinical
anti-cancer portfolio that is patent protected and fully funded to complete pre-clinical development activities and
submit applications to commence clinical trials. In addition to significantly expanding the portfolio, Roquefort
Therapeutics now has a state-of-the-art laboratory in the UK which provides the Group with major cost saving
and time advantages as the Group progresses through the pre-clinical stage of development. The Acquisition
also strengthened the Roquefort Therapeutics Board and senior management with complementary skills and
expertise. The team in place has exceptional experience in drug development and driving and realising value in
biotech. The Acquisition introduced new shareholders into the Group, including Daiichi Sankyo, a global
pharmaceutical Group and CH Health, a specialist biotech venture capital investor – validating the high potential
of the Group’s investment proposition and growth strategy.
Oncogeni has developed two families of innovative cell and RNA oncology medicines, both in pre-clinical
development, which are protected by nine patents and complement the existing Midkine programs well:
l Mesodermal Killer ("MK") cells: a new class of cellular medicine engineered to kill cancer cells both directly
and by enhancing the activity of natural killer cells; and
l Small interfering RNA ("siRNA") therapeutics: kill cancer cells by inhibiting a novel cancer target STAT6 (signal
transducer and activator of transcription 6).
The MK and siRNA families consist of six and four drug candidates each i.e., MK1-6 and siRNA 1-4. Each
candidate is protected by composition of matter patents and has the potential to be a new medicine subject to
the successful completion of development.
The Board and senior management team was significantly expanded with the acquisition of Oncogeni with Ajan
Reginald joining as CEO of Roquefort Therapeutics. Ajan has a strong track record in drug development, biotech
transactions and commercialisation. Over 20 years, he has served as the Global Head of Emerging Technologies
for Roche Group (SWX: ROG), Chief Operating Officer and Chief Technology Officer of Novacyt S.A (LON: NCYT)
and CEO of Celixir Ltd.
In addition, Professor Sir Martin Evans was appointed as Chief Scientific Officer. Sir Martin was the first scientist
to identify embryonic stem cells, which can be adapted for a wide variety of medical purposes. His discoveries
are now being applied in virtually all areas of biomedicine – from basic research to the development of new
therapies. In 2007, he was awarded the Nobel Prize for Medicine, the most prestigious honour in world science,
for these “ground-breaking discoveries concerning embryonic stem cells and DNA recombination in mammals.”
Further, Dr Darrin Disley was appointed Non-Executive Director, and is a renowned scientist, entrepreneur, angel
investor and enterprise champion who has started, grown, or invested in over 40 start-up life science, technology
and social enterprises, raising US$600 million in business financing and closing US$700 million in commercial
deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the company from start-up
through a US$113 million IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to
become a global market leader in gene editing and gene modulation technologies.
Since listing in March 2021, Roquefort Therapeutics has established a quality team, underpinned by a proven
collective track record in the development, progression and commercialisation of relevant medicines, a key aspect
of Roquefort Therapeutics’ investment proposition and leaves the Group well placed, subject to further funding,
to deliver its growth objectives.
Pre-clinical development during 2022
During the period, the Group enhanced the portfolio significantly, completed the integration of the Oncogeni
portfolio. Post the Acquisition, the Group’s portfolio consisted of four fully funded, novel patent-protected
pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists
of:
l Midkine antibodies with significant in vivo efficacy and toxicology studies;
l Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action;
l STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
l MK cell therapy with direct and NK-mediated anti-cancer action.
The Group continued to progress its four novel patent-protected pre-clinical anti-cancer medicines during the
period through a combination of partnerships with leading academic cancer research centres and at the Group's
state of the art laboratory.
With the programs focused on the pre-clinical development of the Midkine antibodies, Midkine RNA
oligonucleotide and STAT-6 siRNA, the Group signed partnership agreements and commenced pre-clinical
development programs with the following leading academic cancer research centres:
l Olivia Newton-John Cancer Research Institute, La Trobe University, Melbourne
o Breast cancer metastasis, Midkine antibody program
l Lowy Cancer Research Centre, University of New South Wales
o Liver and Colorectal cancer, Midkine RNA oligonucleotide and STAT-6 siRNA programs
l Hawkins Laboratory Biochemistry and Genetics, La Trobe University, Melbourne
o Lung cancer metastasis, Midkine antibody program
l School of Medical Sciences, University of Sydney
o Midkine RNA oligonucleotide program
In addition, the Group is utilising its state of the art laboratory in Stratford-upon-Avon to develop the MK cell
therapy program in-house. The laboratory includes a clean room, laminar flow cabinets and cryopreservation
infrastructure required for pre-clinical development of innovative new medicines, particularly cell and gene
therapies.
Post Period End
2023 started with significant momentum, with the Group’s Midkine antibody program, targeting metastatic breast
cancer and metastatic lung cancer, successfully demonstrating in vivo safety in pre-clinical development
4 Roquefort Therapeutics plc
Chairman’s Statement
continued
Chairman’s Statement
continued
programs carried out by leading cancer research groups (stated above), a key development milestone. ROQ-A1
and ROQ-A2 are the patented humanised antibody medicines designed by Roquefort Therapeutics to target the
novel Midkine target prevalent in hard-to-treat cancers. These milestones were completed on schedule and within
budget. Both Midkine antibody candidates will now progress into in vivo pre-clinical efficacy studies to assess
cancer killing ability in primary and metastatic breast cancer and lung cancer. Both antibodies are valuable assets
that fit the established Big Pharma paradigm of treating cancer with novel antibody therapeutics. The siRNA, MK
cell therapy and Midkine RNA oligonucleotide programs are also progressing well and are expected to complete
pre-clinical development milestones in Q2 2023.
The Group has always believed Midkine to be a truly novel target and has been optimistic in the therapeutic
potential of Midkine. In February 2023 Roquefort Therapeutics validated Midkine as a target by signing a Licence
and Royalty agreement with leading diagnostics group, Randox Laboratories in relation to the Group’s Midkine
antibody portfolio. The Group is eligible to receive upfront and potential marketing milestone receipts, as well as
royalties on diagnostics products sold. The Group received from Randox an upfront amount of £200,000 and can
earn further potential milestone receipts of up to £150,000 for marketing approval in certain jurisdictions. The
Group will also receive royalties from Randox on net sales of any commercialised diagnostic products. Randox is
developing a diagnostic to identify patients with cancers that overexpress Midkine which is highly synergistic with
Roquefort Therapeutics’ development of first-in-class cancer medicines. The Licence and Royalty agreement
also benefits the Group’s preparation for clinical trial readiness because diagnosing patients early will accelerate
the ability to diagnose patients for clinical trials which will dramatically reduce time and costs associated, and in
addition, clinical trials with companion diagnostics have a much higher success rate – 15.9% vs 7.6%
(BIO,QSLAdvisors and Informa UK 2021 Report).
Finally in March 2023, Roquefort Therapeutics announced the successful development of a fifth program and a
third in its Midkine family. The Roquefort Therapeutics team led by Vice President of Drug Discovery, Professor
Graham Robertson, has delivered a pioneering mRNA anti-cancer program. This new platform of mRNA
therapeutics was developed in-house and consists of four mRNA pre-clinical therapeutics targeting Roquefort
Therapeutics’ novel Midkine target. Developing the mRNA anti-cancer program is highly synergistic with the
Group’s existing Midkine RNA oligonucleotide program in development at the University of New South Wales,
ensuring development continues to remain on budget and on schedule. The addition of the mRNA family expanded
Roquefort Therapeutics’ portfolio to five highly innovative programs which remain fully funded to the critical value
inflection point of clinical trial readiness. The Group is now working towards demonstrating efficacy of the mRNA
therapeutics in specific cancer targets, alongside the Group’s existing Midkine RNA oligonucleotide program.
Strategy & Outlook
Roquefort Therapeutics’ strategy is to identify the next generation of medicines for the most difficult to treat
cancers which have a high mortality rate, and develop medicines in-house and with academic partners through
the pre-clinical phase to clinical trial readiness and IND filings. The Group has the necessary expertise and
experience to package up the programs for licence or sale to big pharma which is the Group’s ultimate aim to
realise value. Through the material strategic progress delivered over the course of the prior year, Roquefort
Therapeutics is well positioned with currently five pre-clinical programs, and a considerably strengthened team
to deliver significant progress in a focused and cost-effective manner, through a combination of partnerships
with leading academic cancer research centres and a high-quality in-house laboratory.
2023 has started with significant momentum and the Group has laid the foundations to realise this strategy having
expanded the Group in September 2022 and by its pre-clinical and commercial successes announced during
Q12023. The Randox licensing agreement has demonstrated the Group’s ability to achieve deals, and out licencing
to strategic partners, both in diagnostics and therapeutics, is a key priority for Roquefort Therapeutics during
2023. The pre-clinical progress is highly encouraging and the Group will update shareholders as to its further
progress in due course.
The Chairman’s statement should be read as part of the strategic report.
Stephen West,
Executive Chairman
4 June 2023
Annual Report & Financial Statements 2022 5
6 Roquefort Therapeutics plc
Board of Directors
Stephen West,
Executive Chairman
Stephen is a Fellow Chartered Accountant with over 30 years of financial and corporate experience gained in
public practice, the resource sector, life sciences and investment banking. Stephen has a proven track record in
working with growth companies with extensive experience in IPOs, secondary listings, corporate finance,
fundraising and investor relations. Stephen is currently a non-executive director of EnergyPathways Ltd.
Ajan Reginald,
Chief Executive Officer
(appointed 16 September 2022)
Ajan is an experienced biotechnology CEO with a track record in drug development, biotech transactions and
commercialisation. Over 20 years, he has served as the Global Head of Emerging Technologies for Roche Group
(SWX: ROG), Chief Operating Officer and Chief Technology Officer of Novacyt S.A (LON: NCYT) and CEO of Celixir Ltd.
With Prof. Sir Martin Evans, Ajan founded Celixir, and developed a novel cardiac cellular medicine which completed
pre-clinical development and won FDA, MHRA and EU regulatory trial approvals. Celixir completed a licensing for
the Japan market only with Daiichi Sankyo, a Japanese Big Pharma company which included a £12.5 million
upfront payment and a £5 million equity investment which valued Celixir at ~£220M.
Ajan is an alumni of Harvard Business School (AMP) and is recipient of the Fulbright Scholarship. He is also a
graduate of the University of Oxford (MSc Experimental Therapeutics), Kellogg Business School (MBA)
Northwestern University and University of London (BDS). He has represented England at the Hockey Masters
World Cup and European Championships.
Professor Sir Martin Evans, Nobel Laureate,
Chief Scientific Officer
(appointed 16 September 2022)
Sir Martin was the first scientist to identify embryonic stem cells, which can be adapted for a wide variety of
medical purposes. His discoveries are now being applied in virtually all areas of biomedicine - from basic research
to the development of new therapies. In 2007, he was awarded the Nobel Prize for Medicine, the most prestigious
honour in world science, for these "ground-breaking discoveries concerning embryonic stem cells and DNA
recombination in mammals."
Sir Martin has published more than 120 scientific papers. He was elected a Fellow of the Royal Society in 1993
and is a founder Fellow of the Academy of Medical Sciences. He was awarded the Walter Cottman Fellowship
and the William Bate Hardy Prizes in 2003 and in 2001 was awarded the Albert Lasker Medal for Basic Medical
Research in the US. In 2002 he was awarded an honorary doctorate from Mount Sinai School of Medicine in New
York, regarded as one of the world's foremost centres for medical and scientific training. He has also received
honorary doctorate awards from the University of Bath, University of Buckinghamshire, University College London,
University of Wales and the University of Athens. Sir Martin gained his BA in Biochemistry from Christ College,
University of Cambridge in 1963. He received an MA in 1966 and a DSc in 1966. In 1969 he was awarded a
PhDfrom University College, London. He joined the Cardiff University School of Biosciences in 1999. He was
knighted in 2004 for his services to medical science and in 2009 was awarded the Gold Medal of the Royal Society
of Medicine in recognition of his valuable contribution to medicine. In 2009 he also received the Baly Medal from
the Royal College of Physicians and the Copley Medal, the Royal Society's oldest award, joining an eminent list of
previous recipients including Albert Einstein.
Board of Directors and Senior Management
Board of Directors and Senior Management
continued
Annual Report & Financial Statements 2022 7
Dr Darrin Disley, OBE
Non-Executive Director
(appointed 16 September 2022)
Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown,
orinvested in over 40 start-up life science, technology and social enterprises, raising US$600 million in business
financing and closing US$700 million in commercial deals. He was CEO of Horizon Discovery Group plc for
11years, during which he led the company from start-up through a US$113 million IPO, and rapid scale-up
powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and
gene modulation technologies. He was awarded a lifetime Queen's Award for Enterprise Promotion in 2016 for
his work in promoting enterprise across the UK and appointed OBE in 2018 for his services to business and
enterprise in the healthcare sector.
Ms Jean Duvall,
Non-Executive Director
(appointed 5 April 2022)
Jean is highly accomplished in the biotech and pharma sector, with over 25 years experience in executive roles
in the industry. During this time, Jean acted for Ferring Pharmaceuticals, as one of the Executive Board Members
who built the company from a US$700 million to US$2 billion in revenue. Jean has a significant track record in
corporate development having led multiple successful M&A, divestment and licensing deals throughout her career.
She previously had the role of General Counsel at Elan Corporation and was legal lead, negotiating the divestment
of over $2bn in assets. Additionally, she has co-founded and led biopharma start-ups including Trizell and Amzell,
resulting in multiple products having successful phase 2 and 3 clinical studies. Jean is currently CEO and
co-founder of ReproNovo SA and a non-executive director of Ondine Biomedical Inc. (AIM:OBI).
Dr Simon Sinclair,
Non-Executive Director
(appointed 20 April 2022)
Simon is a senior executive physician scientist with over 20 years’ pharma, medtech and consumer healthcare
industry experience. He is currently Chief Safety Officer at Reckitt Benckiser. Simon was previously at Johnson
and Johnson Medical Devices, first as International Clinical Director, then leading Medical Affairs for its EMEA
region. Prior to this, Simon led translational medicine efforts and the early clinical development at Merck and Co
(MSD) in the USA. Originally trained as an ophthalmologist, Simon holds a medical degree and a PhD in neural
transplantation from the University of Cambridge. Simon is currently a non-executive director of Ondine
Biomedical Inc. (AIM:OBI) and a non-executive director at Renovos Biologics Limited.
Dr Michael Stein,
Non-Executive Director
Michael is a business leader and strategic adviser with C-suite experience in healthcare. Michael was the
founding CEO of Valo Therapeutics and of OxStem Ltd. In addition, Michael has served as founding CEO for
Doctor Care Anywhere, acquired by Synergix in 2015. In 2001, he co-founded the Map of Medicine Ltd (the
Map) with University College London. As founding CEO (and later CMO), the Map was nationally licensed across
NHS England (2005-15) and acquired by Hearst Business Media (HBM) in 2008, after which Michael transitioned
to executive vice-president of healthcare innovation. Michael graduated as a medical doctor (Honours) and
biochemist (First Class Honours) from the University of Cape Town (1988) and from the University of Oxford
(Rhodes Scholar) with a doctorate in Physiological Sciences (Immunology).
Board of Directors and Senior Management
continued
8 Roquefort Therapeutics plc
Senior Management
Dr Graham Robertson,
Vice President – Drug Discovery
Dr Robertson gained his PhD in molecular virology from Macquarie University, Australia before undertaking
Post-Doctoral training in gene regulation and nuclear architecture at Oxford. He returned to Australia as a
Post-Doc in the laboratory of Prof. Emma Whitelaw at University of Sydney where he set up a transgenic mouse
facility and discovered repeat-induced silencing as an epigenetic process on mammalian transgenes. Dr
Robertson then moved to Westmead Hospital Millennium Institute where he pursued studies on the fibrotic liver
disease NASH and the impact of inducible xenobiotic/drug interactions on drug clearance pathways. A component
of this work involved creating a transgenic mouse model for studying gene regulation of human CYP3A4, the
main pathway for drug metabolism. The model was subsequently commercially leveraged as a screening tool
for drug development. At the ANZAC and Garvan Institutes in Sydney (2004-2014), Dr Robertson explored the
impact of cancer-associated inflammation in repressing drug clearance leading to excessive toxicity. Dr Robertson
also explored the link between chronic inflammation and disrupted energy metabolism as the basis for cancer
cachexia. A key discovery from this work was the activation of thermogenesis in white & brown fat, linked to body
wasting. These findings were published in Cancer Research and Cell Metabolism where it was ranked amongst
the 10thhighest papers in the latter journal. He has published ~60 papers with >3,000 citations.
Dr Sabena Sultan
Vice President – Drug Development
Dr Sultan studied for her PhD in Cardiovascular Biology at Imperial College London and undertook postdoctoral
research at the Rayne Institute, University College London and worked within the Cardiovascular Department at
Kings College London as a British Heart Foundation Principle Grant Investigator. Dr Sultan was previously Global
Head of Research at Cell Therapy Limited, working to bring cellular therapies to clinic.
Annual Report & Financial Statements 2022 9
The Directors present their report with the audited financial statements of Roquefort Therapeutics plc
(“the Company") and its subsidiaries Lyramid Pty Limited (“Lyramid”), Oncogeni Limited (“Oncogeni”) and
Tumorkine Pty Limited (“Tumorkine”) (together “the Group”) for the year ended 31 December 2022. A commentary
on the business for the year is included in the Chairman’s Statement on page 3. A review of the business is also
included in the Strategic Report on pages 13 to 22.
The Company’s Ordinary Shares are listed on the London Stock Exchange, on the Official List pursuant to
Chapter14 of the Listing Rules, which sets out the requirements for Standard Listings.
Directors
The Directors of the Company during the year and their beneficial interest in the Ordinary shares of the Company
at 31 December 2022 were as follows:
Ordinary
Director Position Appointed shares Warrants
Stephen West
1
Executive Chairman 17/08/2020 5,313,264 7,500,000
Ajan Reginald Chief Executive Officer 16/09/2022 11,627,786 –
Sir Martin Evans Chief Scientific Officer 16/09/2022 – –
Dr Michael Stein Non-Executive Director 22/03/2021 – 2,000,000
Ms Jean Duvall Non-Executive Director 05/04/2022 – 300,000
Dr Simon Sinclair
2
Non-Executive Director 20/04/2022 60,415 300,000
Dr Darrin Disley Non-Executive Director 16/09/2022 1,225,966 –
1
4,628,485 Ordinary shares and 7,500,000 warrants held by Cresthaven Investments Pty Ltd ATF The Bellini Trust; and 684,779 Ordinary shares were held by
StephenWest direct
2
300,000 warrants held by Livingstone Investment Holdings Ltd; and 60,415 Ordinary shares were held by Simon Sinclair direct
Qualifying Third Party Indemnity Provision
At the date of this report, the Company has a third-party indemnity policy in place for all Directors.
Substantial shareholders
As at 31 December 2022, the total number of issued Ordinary Shares with voting rights in the Company was
129,149,998. Details of the Company’s capital structure and voting rights are set out in note 18 to the financial
statements.
The Company has been notified of the following interests of 3 per cent or more in its issued share capital as at
the date of approval of this report.
Number of % of
Party Name Ordinary Shares Share Capital
Ajan Reginald 11,627,786 9.00%
Abdelatif Lachab 7,750,000 6.00%
Jane Whiddon
1
7,300,000 5.65%
M Sheikh 5,744,870 4.45%
Stephen West
2
5,313,264 4.11%
Provelmare SA 5,000,000 3.87%
Z Sheikh 4,018,910 3.11%
M Rollins 4,000,000 3.10%
K Fallon 3,905,215 3.02%
1
2,500,000 shares held by MIMO Strategies Pty Ltd (ATF the MIMO Trust); 4,100,000 shares held by 6466 Investments Pty Ltd; 700,000 shares held by Nautical
Holdings WA Pty Ltd – all of which are entities controlled by J Whiddon
2
4,628,484 shares held by Cresthaven Investments Pty Ltd (ATF the Bellini Trust) – an entity associated with S West
Directors’ Report
10 Roquefort Therapeutics plc
Financial instruments
Details of the Company’s financial risk management objectives and policies as well as exposure to financial risk
are contained in the accounting policies and note 21 of the financial statements.
Greenhouse Gas (GHG) Emissions
The Company is aware that it needs to measure its operational carbon footprint in order to limit and control its
environmental impact. However, due to its operational footprint being limited to a laboratory leased from August
2022, consuming less than 40,000 kWh of energy, the Company is currently exempt from GHG reporting
requirements.
In the future, the Company will only measure the impact of its direct activities, as the full impact of the entire
supply chain of its suppliers cannot be measured practically.
TCFD Disclosure
The Group was incorporated in August 2020, and operated virtually until its acquisition of Oncogeni Limited in
September 2022, at which point the Group commenced a short-term lease of laboratory and office facilities. The
Group therefore will begin to consider its impact on the environment and the risks it faces from climate change,
for the first time during 2023 and expects to develop its sustainability plans over a 5 year period, commensurate
with the size of its operations. Climate change was not considered a principal risk or uncertainty for the year
ended 31 December 2022.
In line with the requirements of the Financial Conduct Authority’s Listing Rule 14.3.27R, and for the above reasons,
we note that we have not made the disclosures, in respect of the financial year ended 31 December 2022, in line
with the recommendations and recommended disclosures of the TCFD.
Dividends
The Directors do not propose a dividend in respect of the year ended 31 December 2022.
Research and development, Future developments and events subsequent to the
year end
Further details of the Company’s research and development, future developments and events subsequent to the
year-end are set out in the Strategic Report on pages 13 to 22. Research and development costs incurred for the
year ended 31 December 2022 were £319,315 (2021 - £698).
Corporate Governance
The Governance report forms part of the Director’s Report and is disclosed on pages 23 to 26.
Going Concern
The Directors have prepared financial forecasts to estimate the likely cash requirements of the Group over the
period to 30 June 2024, given its stage of development and lack of recurring revenues. In preparing these financial
forecasts, the Directors have made certain assumptions with regards to the timing and amount of future
expenditure over which they have control. The Directors have considered the sensitivity of the financial forecasts
to changes in key assumptions, including, among others, potential cost overruns within committed spend and
changes in exchange rates.
The Group’s available resources are sufficient to cover the Group’s plans to complete pre-clinical development
activities and submit applications to commence clinical trials during 2023, however, they are not sufficient to
cover existing committed costs and the costs of planned activities for at least 12 months from the date of signing
these consolidated and company financial statements.
Directors’ Report
continued
Annual Report & Financial Statements 2022 11
The Directors plan to raise further funds during 2023 (either through licencing deals and/or equity placements)
and have reasonable expectations that sufficient cash will be raised to fund the planned operations of the Group
for a period of at least 12 months from the date of approval of these financial statements. The funding requirement
indicates that a material uncertainty exists which may cast significant doubt over the Group’s and Company’s
ability to continue as a going concern, and therefore its ability to realise its assets and discharge its liabilities in
the normal course of business.
After due consideration of these forecasts, current cash resources, including the sensitivity of key inputs, and
plans to raise further funds, the Directors consider that the Group will have adequate financial resources to
continue in operational existence for the foreseeable future (being a period of at least 12 months from the date
of this report) and, for this reason, the financial statements have been prepared on a going concern basis. The
financial statements do not include the adjustments that would be required should the going concern basis of
preparation no longer be appropriate.
Principal Activities
The Company’s principal activity in the reporting period was the preclinical development of next generation
medicines focused on hard to treat cancers.
Auditors
On 1 December 2022, Jeffreys Henry LLP resigned as the Company's auditors and confirmed that there are no
circumstances connected with their resignation which they considered should be brought to the attention of the
Company's members or creditors in accordance with Section 519 of the Companies Act 2006.
On 16 January 2023 it was announced that the Company had appointed BDO LLP as its auditors with immediate
effect. The appointment of BDO LLP will be subject to approval by shareholders at the next Annual General Meeting
of the Company.
Statement of Directors’ responsibilities
The Directors are responsible for preparing the Annual Report alongside the financial statements in accordance
with applicable law and regulations.
Company law requires the Directors to prepare financial statements for each financial year. Under that law the
Directors have prepared the financial statements in accordance with UK adopted International Accounting
Standards.
Under company law the Directors must not approve the financial statements unless they are satisfied that they
give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that
year. The Directors are also required to prepare financial statements in accordance with the rules of the London
Stock Exchange for companies with a Standard Listing.
In preparing these financial statements, the Directors are required to:
l Select suitable accounting policies and then apply them consistently;
l Make judgments and accounting estimates that are reasonable and prudent;
l State whether applicable UK adopted International Accounting Standards have been followed, subject to
any material departures disclosed and explained in the financial statements; and
l Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the
Company will continue in business.
Directors’ Report
continued
Directors’ Report
continued
The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain
the Company’s transactions and disclose with reasonable accuracy at any time the financial position of the
Company and enable them to ensure that the financial statements and the Remuneration Committee Report
comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and
hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. They are also
responsible to make a statement that they consider that the annual report and accounts, taken as a whole, is fair,
balanced, and understandable and provides the information necessary for the shareholders to assess the
Company’s position and performance, business model and strategy.
The Directors are responsible for the maintenance and integrity of the corporate and financial information included
on the Company’s website. Legislation in the United Kingdom governing the preparation and dissemination of
the financial statements may differ from legislation in other jurisdictions.
Statement of Directors’ responsibilities pursuant to Disclosure and
TransparencyRules
Each of the Directors, whose names and functions are listed on pages 6 and 7 confirm that, to the best of their
knowledge and belief:
l the financial statements prepared in accordance with UK adopted International Accounting Standards, give
a true and fair view of the assets, liabilities, financial position and loss of the Group and Company; and
l the Annual Report and financial statements, including the Strategic Report, includes a fair review of the
development and performance of the business and the position of the Group and Company, together with
a description of the principal risks and uncertainties that they face.
Disclosure of Information to Auditors
So far as the Directors are aware, there is no relevant audit information of which the Company’s auditors are
unaware, and each Director has taken all the steps that they ought to have taken as a Director in order to make
themselves aware of any relevant audit information and to establish that the Company’s auditors are aware of
that information.
This directors’ report was approved by the Board of Directors on 4 June 2023 and is signed on its behalf by:
Stephen West,
Executive Chairman
12 Roquefort Therapeutics plc
Strategic Report
Annual Report & Financial Statements 2022 13
The Directors present the Strategic Report of the Company and the Group for the year ended 31 December 2022.
Section 172(1) Statement - Promotion of the Company for the benefit of the
members as a whole
The Directors believe they have acted in the way most likely to promote the success of the Company for the
benefit of its members as a whole, as required by s172 of the Companies Act 2006.
The requirements of s172 are for the Directors to:
l Consider the likely consequences of any decision in the long term;
l Act fairly between the members of the Company;
l Maintain a reputation for high standards of business conduct;
l Consider the interests of the Company’s employees;
l Foster the Company’s relationships with suppliers, customers and others; and
l Consider the impact of the Company’s operations on the community and the environment.
The Company acquired Lyramid Pty Ltd in late 2021 and then subsequently acquired Oncogeni Limited in
September 2022. The pre-revenue nature of the business is important to the understanding of the Company by
its members and suppliers, and the Directors are as transparent about the cash position and funding requirements
as is allowed under LSE regulations.
We aim to work responsibly with our stakeholders, including suppliers. The key Board decisions made in the year
and post year end are set out below:
Significant events / decisions Key s172 matter(s) affected Actions and Consequences
Entering into an agreement to Shareholders and Business Completion of the acquisition
purchase the entire issued share Relationships and associated Placing, with
capital of Oncogeni Limited and the the enlarged share capital
associated Share Placing listed on the London Stock
Exchange, leading to
greater likely outcomes
for shareholders in the
future. Shareholders were
communicated to and
decisions made by the
Directors were notified via the
Regulatory New Service.
Interests of Employees
The Company’s Corporate Governance Statement at pages 23 to 26 of this Annual Report sets out (under board
responsibilities) the processes in place to safeguard the interests of employees.
Foster business relationships with suppliers, joint venture partners and others
Potential suppliers and joint venture partners are considered in the light of their suitability to comply with the
Company’s policies.
Impact of operations on the community and environment
The Company will continue to monitor the impact of its research facilities on the community and environment.
Strategic Report
continued
14 Roquefort Therapeutics plc
Maintain a reputation for high standards of business conduct
The Corporate Governance section of this Annual Report at pages 23 to 26 sets out the Board and Committee
structures and Board and Committee meetings held during the year, together with the experience of executive
management and the Board and the Company's policies and procedures.
Act fairly as between members of the Company
The Board takes feedback from a wide range of shareholders (large and small) and endeavours at every
opportunity to pro-actively engage with all shareholders (via regulatory news reporting-RNS) and engage with
any specific shareholders in response to particular queries they may have from time to time. The Board considers
that its key decisions during the year have impacted equally on all members of the Company.
Review of Business in the Year
Operational Review
The Company’s principal activity is set out in the Directors’ Report on page 11.
During the first nine months of the year under review the Company was primarily focused on the pre-clinical
development of RNA oligonucleotide drugs targeting Midkine. These RNA oligonucleotide drugs interfere with
processing of the Midkine mRNA ultimately leading to reduced active Midkine protein produced in diseased tissues
and tumours.
On 22 June 2022 the Company announced that it had entered into a conditional sale and purchase agreement
with the shareholders of Oncogeni Limited (“Oncogeni”) to acquire 100% of the total issued equity in Oncogeni
for an aggregate consideration of £3,750,000 to be satisfied by the issue of 50,000,000 new ordinary shares in
theCompany.
Oncogeni was established in 2019 by Nobel Laureate Professor Sir Martin Evans. It had an experienced leadership
team developing novel cell and RNA based cancer medicines, which the Board believed were complementary to
the Company's existing pre-clinical drug development business.
To fund the future pre-clinical drug development work of Oncogeni and the working capital requirements of the
enlarged Group, the Company also announced a placing of 7,249,998 new ordinary shares to new and existing
investors to raise funds of £1.015 million.
The transaction and placing were successfully completed on 16 September 2022 with 57,249,998 new ordinary
shares being issued and admitted to the Official List of the UKLA by way of a standard listing under Chapter 14
of the UKLA's Listing Rules and to trading on the London Stock Exchange's main market for listed securities on
thatdate.
On completion of the transaction Professor Sir Martin Evans, Ajan Reginald and Dr Darrin Disley (all directors of
Oncogeni) were appointed to the Board of the Company.
Post-acquisition of Oncogeni the Company was focused on integrating the Oncogeni business into the existing
business and progressing development of the enlarged pre-clinical drug portfolio.
Events since the year end
On 20 February 2023 the Company announced that it had signed an exclusive licence and royalty agreement, for
the field of medical diagnostics only, with a leading international diagnostics company, Randox Laboratories Ltd
("Randox"), in relation to its Midkine antibody portfolio. Randox and Roquefort Therapeutics will now engage in
collaborative research programs to develop new cancer diagnostics that will identify patients treatable with the
Company's Midkine therapeutics.
On 8 March 2023 the Company announced that it had successfully developed a new novel platform of anti-cancer
mRNA therapeutics.
Strategic Report
continued
Annual Report & Financial Statements 2022 15
Financial review
Results for the year to 31 December 2022
The Consolidated Statement of Comprehensive Income for the year shows a loss of £1,615,417 (2021: £917,433)
and the Consolidated Statement of Financial Position at 31 December 2022 shows net assets of £7,206,638
(2021: £4,082,606) for the Group.
The total comprehensive loss for the year of £1,630,406 (2021: loss of £916,809) occurred as a result of on-going
research and development costs, and administrative expenses required to operate the Company, and costs in
relation to the completion of the acquisition of Oncogeni.
Administrative expenses increased to £1,306,561 (2021: £252,392) mainly due to Directors’ and employee costs
increasing to £365,564 (2021: £59,607), consulting and professional fees increasing to £209,768 (2021: £125,807),
the audit fee increasing to £157,336 (2021: £22,000) and other expenditure (excluding audit fees) increasing to
£527,520 (2021: £13,818) – reflecting an increase in staff and operational activities during the year. Research
and development expenditure increased to £319,315 (2021: £698) as the Group carried out external studies with
Murdoch University for the Midkine RNA oligonucleotide pre-clinical program in the first half of the year and
commenced internal and external studies on the other programs later in the year.
The intangible assets of the Group increased to £5,343,506 (2021: £1,481,530) as a result of accounting for the
fair value of shares issued for the acquisition of Oncogeni Limited (Refer to note 12).
Other receivables reduced significantly to £45,154 (2021: £2,135,031) due to the receipt of outstanding placing
proceeds of £2,106,202 in January 2022.
Cash flow
Net cash inflow for the Group for 2022 was £1,421,258 (2021: £900,335).
Net cash used in investing activities for 2022 decreased to £122,468 (2021: £606,226) reflecting the acquisition
of Oncogeni Limited in 2022 for equity consideration and associated costs, compared with the acquisition of
Lyramid Pty Ltd in 2021 for a mixture of cash consideration, equity consideration and associated costs.
Net flows from financing activities for 2022 was £3,121,202 reflecting the receipt of proceeds from an equity
placement undertaken in December 2021 of £2,106,202 and an equity placement in September 2022 raising
£1,014,999. This compares to the net flows from financing activities for 2021 of £2,023,393 reflecting, after costs
of £159,405, pre-IPO equity placements in 2020 raising £124,000, the IPO equity placement in March 2021 raising
£1,000,000, the exercise of broker warrants for £15,000, an equity placement in August 2021 raising £150,000
and an equity placement in December 2021 raising £3,000,000 (less proceeds outstanding and received in early
2022 of £2,106,202).
Closing cash
As at 31 December 2022, the Group held £2,322,974 (2021: £899,721) of cash.
Key Performance Indicators
The Company’s non-financial KPIs are the development of new novel anti-cancer therapeutics, the registration
of new patents to protect the clinical advancements in anti-cancer therapeutics being achieved during the pre-
clinical stages of drug discovery and entering into licencing deals with other companies.
The Company’s financial KPIs are the Company’s cash runway and budgeted R&D spend compared to actuals.
16 Roquefort Therapeutics plc
Position of Company’s Business
At the year end
At the year end the Company’s Statement of Financial Position shows net assets totalling £7,481,382 (2021:
£4,014,683). The Company’s current cash resources are sufficient to cover the Company’s plans to complete
pre-clinical development activities and submit applications to commence clinical trials for all of the Company’s
pre-clinical programs. However, the ability of the Company to continue as a going concern, for at least 12 months
from the date of signing this Annual Report, is dependent upon the completion of licencing deals that include
upfront consideration and/or the successful future raising of further capital, which the Directors are confident of
achieving. There can be no assurance that these plans will be successful and so there is a material uncertainty
over the Company’s ability to continue as a going concern.
Environmental matters
The Board contains personnel with a good history of running businesses that have been compliant with all relevant
laws and regulations and there have been no instances of non-compliance in respect of environmental matters.
Employee information
As at the date of this report, the Company has an Executive Chairman, two Executive Directors and
fourNon-Executive Directors. The Company is committed to gender equality and, as future roles are identified, a
wide-ranging search would be completed with the most appropriate individual being appointed irrespective
ofgender.
A split of our employees and directors by gender at the date of this report, is shown below:
Male Female
Directors 6 1
Employees – 2
Total employees (including directors) 6 3
Social/Community/Human rights matters
The Company ensures that employment practices take into account the necessary diversity requirements and
compliance with all employment laws. The Board has experience in dealing with such issues and sufficient training
and qualifications to ensure they meet all requirements.
Anti-corruption and anti-bribery policy
The government of the United Kingdom has issued guidelines setting out appropriate procedures for companies
to follow to ensure that they are compliant with the UK Bribery Act 2010. The Company has conducted a review
into its operational procedures to consider the impact of the Bribery Act 2010 and the Board has adopted an
anti-corruption and anti-bribery policy.
Strategic Report
continued
Annual Report & Financial Statements 2022 17
Principal Risks and Uncertainties
The Group operates in an uncertain environment and is subject to a number of risk factors. The Directors consider
the following risk factors are of particular relevance to the Group’s activities although it should be noted that this
list is not exhaustive and that other risk factors not presently known or currently deemed immaterial may apply.
Issue Risk/Uncertainty Mitigation
The Directors will engage in
continuous dialogue with the Chief
Scientific Officer to critically review
the technical risks. The Board has
established a Scientific Advisory
Board to support them in this
review process.
All therapeutic research and development
programs carry technical risks, including
the programs undertaken by the Group.
These risks include: those associated with
delays in development of effective and
potent drugs; failure of delivery by third
party suppliers of research services or
materials essential to the programs; and
outcomes of clinical testing. There is no
guarantee that these technical risks can be
effectively overcome, and a successful,
approved product can be developed.
Furthermore, the Group is pursuing
relatively new drug classes. Whilst several
examples of approved drugs now exist in
these classes, as yet no such drug has been
developed for the Group’s targets. There is
a risk that these novel classes of drugs may
not be an effective way of modulating the
target’s expression to exert appropriate
clinical benefit in the target conditions.
Research and development
risks carry technical risks,
including the programs
undertaken by the Group
and there is no guarantee
that these technical risks
can be effectively overcome,
and a successful, approved
product can be developed
The Directors have appointed a
CEO to actively manage the
commercial activities of the Group
as it develops.
The CEO and the Directors will
oversee the progress of the
development of the Group’s
research programs and associated
technologies and will ensure
funding is in place to support the
necessary trials and further
development steps as these come
on stream.
The generation of revenues is difficult to
predict and there is no guarantee that the
Group will generate significant or any
revenues in the foreseeable future.
The Group will face risks frequently
encountered by pre-revenue businesses
looking to bring new products and devices
to the market. There is also no guarantee
that the intellectual property held will
ultimately result in a commercially viable
product. It is also possible that technical
and/or regulatory hurdles could lengthen
the time required for the delivery of such a
testing product.
The Group’s future growth will also depend
on its ability to secure commercialisation
partnerships on appropriate terms, to
manage growth and to expand and improve
operational, financial and management
information, quality control systems and its
commercialisation function on a timely
basis, whilst at the same time maintaining
effective cost controls.
The Group is a pre-revenue
business and there is no
guarantee that it will
generate significant or any
revenue in the near future
Strategic Report
continued
18 Roquefort Therapeutics plc
Issue Risk/Uncertainty Mitigation
The Scientific Advisory Board will
be critical in supporting the Board
in understanding and mitigating
these risks. Even so, a sudden
unforeseen change in the
regulations could have a material
adverse impact on the
development program.
The Group cannot guarantee that
the proposed development work
will result in an efficacious
treatment, or even if it does, that the
drug will be approved by regulatory
authorities.
Biotechnology programs are subject to
the most stringent regulatory oversight by
various government agencies and ethics
committees. Key regulatory focus areas
are safety and efficacy, and future clinical
trials conducted by the Group may be
suspended or abandoned entirely in the
event that regulatory agencies consider
that continuation of these trials could
expose participants to undue risks. Before
obtaining regulatory approval of a product
for a target indication, substantial
evidence must be gathered in controlled
clinical trials that the product candidate is
safe and effective for use for that clinical
setting. Similar approvals must be
obtained from the relevant regulatory
authorities in each country in which the
product may be made available, including
Australia, US and the EU.
Biotechnology programs
are subject to the most
stringent regulatory
oversight by various
government agencies and
ethics committees and
there is no guarantee that
the proposed development
work will result in an
efficacious treatment, or
even if it does, that the drug
will be approved by
regulatory authorities
During 2022, the Board appointed
new Directors, senior management
and advisors with appropriate
experience and expertise to give the
Group the best chance of
commercialising any successful
drug in the future.
There may be other companies
developing effective treatments for the
same conditions as the Group, which
could make commercialising any drug
more difficult. The research and
development programs planned are
expected to take several years before any
drug might be ready and the market for
such drugs may contract significantly or
become too competitive for an
economically viable drug launch. In
addition, even post regulatory approval,
any drug may need to be withdrawn from
the market, as well as expose the Group
to claims for compensation as a result of
serious adverse events associated with
the treatment. Historically, very few drugs
make it from discovery to regulatory
approval and commercialisation.
Even where the Group is
successful in terms of
technical and regulatory
approvals, there is no
guarantee it will be
successful in securing an
appropriate licensing deal
or in achieving alternative
means of commercialising
its drugs
Strategic Report
continued
Annual Report & Financial Statements 2022 19
Issue Risk/Uncertainty Mitigation
The CEO has a good understanding
of the details of the licence
agreements and the Group’s
obligations under them. Should any
areas of concern arise, legal
counsel will be sought before
further steps are taken.
The Group’s subsidiary Lyramid Pty Ltd
operates its Midkine antibody research
and development programs under a
worldwide, licence agreement with
Anagenics Ltd, the owner of the Midkine
patents. Similarly, the Group’s subsidiary
Oncogeni Ltd operates its MK Cell and
siRNA programs under worldwide
licencing agreements with Cell Therapy
Limited and Sirna Limited respectively.
Whilst the Group is currently compliant,
there is a risk that the rights to these
patents, as defined by the relevant licence
agreement, will be forfeited by virtue of
either party failing to meet licence
conditions.
Existing patents and
licences are subject to the
terms and conditions of the
relevant licence agreement
which could be terminated
for non-compliance with
the terms of such licence
agreement
The Group seeks to protect its
intellectual property through the
filing of patent applications, as well
as robust confidentiality obligations
on its employees.
The Board intends to defend the
Group’s intellectual property
vigorously, where necessary
through litigation and other means.
The Group’s ability to compete will
depend in part, upon the successful
protection of its intellectual property, in
particular its Patents Rights and Know-
How. Filing, prosecuting and defending
patents in all countries throughout the
world would be prohibitively expensive. It
is possible that competitors will use the
technologies in jurisdictions where the
Group has not registered patents.
Any such claims are likely to be expensive
to defend, and the other litigating parties
may be able to sustain the costs of
complex patent litigation more effectively
than the Group can, because they have
substantially greater resources. Moreover,
even if the Group is successful in
defending any infringement proceedings,
it may incur substantial costs and divert
management’s time and attention in
doing so, which may have a material
adverse effect on the Group’s business,
financial condition, capital resources,
results and/or future operations. Further,
disputes can often last for a number of
years, and can be subject to lengthy
appeals processes before any final
resolution is achieved through the various
different courts and/or tribunals.
Furthermore, it cannot be guaranteed that
a court will not rule against the Group
were such claims to be defended.
The Group’s ability to
compete will depend in part,
upon the successful
protection of its intellectual
property, in particular its
patents and know-how
Strategic Report
continued
20 Roquefort Therapeutics plc
Issue Risk/Uncertainty Mitigation
Despite these precautions that may be
taken by the Group to protect its
intellectual technology and products,
unauthorised third parties may attempt to
copy, or obtain and use its technology and
products. A third party may infringe upon
the Group’s intellectual property, release
information considered confidential about
the Group’s intellectual property and/or
claim technology that is registered to the
Group. In addition, the Group may fail to
discover infringement of its intellectual
property, and/or any steps taken or that
will be taken by it may not be sufficient to
protect its intellectual property rights or
prevent others from seeking to invalidate
its intellectual property (for example, in
response to a claim for infringement or
where an attempt is made to “clear a path”
for a new competing product) or block
sales of its products by alleging a breach
of their intellectual property. Third parties
can bring material and arguments which
the patent office granting the patent may
not have seen at the time of granting the
patent. Therefore, whilst a patent may be
granted to the Group it could in the future
be found by a court of law or by a patent
office to be invalid or unenforceable or in
need of further restriction. As a result of a
validity challenge, a patent may be
amended so as to narrow its scope to an
extent that it may be more difficult to
restrict activities of competitors.
Applications filed by the Group in respect
of new patents and trademarks may also
not be granted or, if granted, may still be
subject to opposition. In addition, there can
be no guarantee that the patents or
trademarks will be granted on a timely
basis. Subject to certain time limits, there
may, in certain circumstances, also be
claims to entitlement, and/or
compensation arising from contributions
made, to granted patents by those who
have assisted with the relevant research or
project.
Strategic Report
continued
Annual Report & Financial Statements 2022 21
Issue Risk/Uncertainty Mitigation
In the event that litigation is necessary in
the future in order to enforce the Group’s
intellectual property rights, determine the
scope and validity of proprietary rights of
other companies, and/or defend claims of
infringement or invalidity, it could require
the Group to commit significant resource
to pursue the protection of its intellectual
property and there is no guarantee that
the result of such litigation would result in
a favourable outcome to the Group, or the
damages or other remedies awarded, if
any, may not be commercially meaningful
or represent acceptable compensation in
respect to the infringement.
The Group is not currently aware of any
such active or pending litigation risk.
The Board will be monitoring the
speed and output of the programs
closely and challenging where it
believes things could be done more
quickly.
The Board is aware of the potential
need for further funding as the
programs develop. Being a listed
company gives the Group the ability
to raise more funds in the future
should they be required.
The Group operates within the
biotechnology sector, a complex area of the
healthcare industry. Rapid scientific and
technological change within the
biotechnology sector could lead to other
market participants creating approaches,
products and services equivalent or
superior to the diagnostic testing products
and services than those to be offered by
the Group, which could adversely affect the
Group’s performance and success. Better
resourced competitors may be able to
devote more time and capital towards the
research and development process, which,
in turn, could lead to scientific and/or
technological breakthroughs that may
materially alter the outlook or focus for
markets in which the Group will operate.
If the Group is unable to keep pace with the
changes in the biotechnology sector and in
the wider healthcare industry, the demand
for its platforms and associated products
and services could fall, which may have a
material adverse effect on the Group’s
business, financial condition, capital
resources, results and/or future operations.
In addition, certain of the Group’s
competitors may have significantly greater
financial and human resource capacity and,
as such, better manufacturing capability or
sales and marketing expertise. New
companies with alternative technologies
and products may also emerge.
Competition and the pace of
development in the
biotechnology sector could
lead to the market
participants creating
approaches, products and
services equivalent or
superior to the diagnostic
testing products and
services than those to be
offered by the Group
Strategic Report
continued
22 Roquefort Therapeutics plc
Issue Risk/Uncertainty Mitigation
Composition of the Board
A full analysis of the Board, its function, composition and policies, is included in the Governance Report.
Capital structure
The Company’s capital consists of ordinary shares which rank pari passu in all respects which are traded on the
Standard segment of the Main Market of the London Stock Exchange. There are no restrictions on the transfer of
securities in the Company or restrictions on voting rights and none of the Company’s shares are owned or
controlled by employee share schemes. There are no arrangements in place between shareholders that are known
to the Company that may restrict voting rights, restrict the transfer of securities, result in the appointment or
replacement of Directors, amend the Company’s Articles of Association or restrict the powers of the Company’s
Directors, including in relation to the issuing or buying back by the Company of its shares or any significant
agreements to which the Company is a party that take effect after or terminate upon, a change of control of the
Company following a takeover bid or arrangements between the Company and its Directors or employees
providing for compensation for loss of office or employment (whether through resignation, purported redundancy
or otherwise) that may occur because of a takeover bid.
Approved by the Board on 4 June 2023
Stephen West,
Executive Chairman
The Group offers incentives to
Directors and employees through
share warrants, which makes them
linked to the long-term success of
the business.
The successful operation of the Group
will depend partly upon the performance
and expertise of its current and future
management and employees. The loss of
the services of certain of these members
of the Group’s key management,
including Ajan Reginald, the CEO,
Professor Sir Martin Evans, the Chief
Scientific Officer, and Dr Graham
Robertson, the Vice President of Drug
Discovery or the inability to identify,
attract and retain a sufficient number of
suitably skilled and qualified employees
may have a material adverse effect on
the Group. Any future expansion of the
Group may require considerable
management time which may in turn
inhibit management’s ability to conduct
the day to day business of the Group.
The successful operation of
the Group will depend partly
upon the performance and
expertise of its current and
future management and
employees
Strategic Report
continued
Annual Report & Financial Statements 2022 23
Governance Report
Introduction
The Directors acknowledge the importance of high standards of corporate governance and endeavours, given
the Company’s size and the constitution of the Board, to comply with the principles set out in the QCA Corporate
Governance Code that are relevant to the Group. The QCA Code sets out a standard of minimum best practice for
small and mid-size quoted companies.
Compliance with the QCA Code
Set out below are the Company’s corporate governance practices for the year ended 31 December 2022. Following
the enlargement of the Group with the acquisition of Oncogeni these corporate governance practices are being
considered and reviewed to ensure they remain appropriate.
Maintain governance structures and processes that are fit for purpose and support good decision making by the
board
The Board is responsible for the determination of the investment decisions of the Company and for its overall
supervision via the investment policy and the objectives that it has set out. At the date of this report, the Board
comprises seven Directors, three of whom are Executive Directors and four are Non-Executive Directors, reflecting
a blend of different experiences and backgrounds.
The QCA Code states that a company should have at least two independent non-executive directors. The
Company had six independent non-executive directors active during the year being Michael Stein, Mark Rollins,
Mark Freeman, Jean Duvall, Simon Sinclair and Darrin Disley. At any one time a minimum of three of these were
in office and at the year end four were in office. The Board believes that its composition brings a desirable range
of skills and experience in light of the Company’s challenges and opportunities, while at the same time ensuring
that no individual (or a small group of individuals) can dominate the Board’s decision making. The Company will
appraise the structure of the Board on an ongoing basis.
All new Directors received an informal induction as soon as practical on joining the Board. No formal induction
process exists for new Directors, given the size of the Company, but the Chairman ensures that each individual is
given a tailored introduction to the Company and fully understands the requirements of the role.
A Director has a duty to avoid a situation in which he or she has, or can have, a direct or indirect interest that
conflicts, or possibly may conflict with the interests of the Company. The Board had satisfied itself that there is
no compromise to the independence of those Directors who have appointments on the Boards of, or relationships
with, companies outside the Company. The Board requires Directors to declare all appointments and other
situations which could result in a possible conflict of interest.
The Board intends to meet formally at least six times each year to review, formulate and approve the Group’s
strategy, budgets, and corporate actions and oversee the Group’s progress towards its goals, and to ensure the
Directors maintain overall control and supervision of the Company’s affairs.
Attendance at meetings in the year:
Member Position Meetings attended
Stephen West Executive Chairman 6 of 6
Ajan Reginald Chief Executive Officer 1 of 1
Sir Martin Evans Chief Scientific Officer 1 of 1
Dr Michael Stein Non-Executive Director 5 of 6
Ms Jean Duvall Non-Executive Director 5 of 5
Dr Simon Sinclair Non-Executive Director 5 of 5
Dr Darrin Disley Non-Executive Director 1 of 1
Mark Rollins Non-Executive Director 1 of 1
Mark Freeman Non-Executive Director 3 of 5
The Board is pleased with the high level of attendance and participation of Directors at Board meetings.
24 Roquefort Therapeutics plc
Governance Report
continued
At each Board meeting the Executive Chairman, Stephen West, proposes and seeks agreement to the Board
Agenda and ensures adequate time for discussion.
The Board maintains regular contact with all its service providers and are kept fully informed of investment and
financial controls and any other matters that should be brought to the attention of the Directors. The Directors
also have access where necessary to independent professional advice at the expense of the Company.
Audit Committee
The Company has established an Audit Committee with delegated duties and responsibilities.
The Audit Committee has the primary responsibility of monitoring the quality of internal controls to ensure that
the financial performance of the Group is properly measured and reported on. It receives and reviews reports
from the Group’s management and external auditors relating to the interim and annual accounts and the
accounting and internal control systems in use throughout the Group. The Audit Committee meets not less than
three times in each financial year and has unrestricted access to the Group’s external auditors. Prior to the
acquisition of Oncogeni on 16 September 2022, the Audit Committee comprised Mark Freeman (as chair) and Dr
Michael Stein. From 16 September 2022 the Audit Committee comprised Jean Duvall (as chair) and Dr Michael
Stein. All members of the Audit Committee are non-executive directors.
The Audit Committee meets with the auditors at least twice a year and more frequently if required.
Terms of reference of the Audit Committee will be made available upon written request.
The Audit Committee report is included on pages 33 to 34.
Remuneration Committee
The Company has established a Remuneration Committee to assist the Board in determining its responsibilities
in relation to remuneration, including making recommendations to the Board on the policy on remuneration.
The Remuneration Committee reviews the performance of executive directors, chairman of the Board and senior
management of the Group and makes recommendations to the Board on matters relating to their remuneration
and terms of service. The Remuneration Committee also makes recommendations to the Board on proposals for
the granting of share options and other equity incentives pursuant to any employee share option scheme or equity
incentive plans in operation from time to time. The Remuneration Committee meets as and when necessary, but
at least twice each year. In exercising this role, the Directors shall have regard to the recommendations put forward
in the QCA Code and, where appropriate, the QCA Remuneration Committee Guide and associated guidance. The
members of the Remuneration Committee include two Non-Executive Directors. Prior to 4 April 2022, the
Remuneration Committee comprised Mark Rollins (as chair) and Mark Freeman. On 28 April 2022 Jean Duvall
was appointed as chair of the Remuneration Committee, with Dr Michael Stein acting as a temporary member
during the interim period between the date of Mark Rollins resignation and the appointment of Jean Duvall. From
16 September 2022 the Remuneration Committee comprised Darrin Disley (as chair) and Jean Duvall.
Formal terms of reference for the Remuneration Committee will be made available upon written request.
The Remuneration Committee report is included on pages 27 to 32.
Nomination Committee
The Company has established a Nomination Committee. The Nomination Committee leads the process for board
appointments and makes recommendations to the Board. The Nomination Committee evaluates the balance of
skills, experience, independence and knowledge on the Board and, in the light of this evaluation, prepare a
description of the role and capabilities required for a particular appointment. The Nomination Committee meets
as and when necessary, but at least twice each year. The Nomination Committee comprised Dr Michael Stein (as
chair) and Mark Freeman during the period to 28 April 2022 when Mark Freeman resigned from, and
Dr Simon Sinclair was appointed to, the Nomination Committee.
Annual Report & Financial Statements 2022 25
Governance Report
continued
Terms of reference for the Nomination Committee will be made available upon written request.
The Nomination Committee report is included on page 35.
Market Abuse Regulations
The Company has adopted a share dealing policy, in conformity with the requirements of the Listing Rules and
the Market Abuse Regulation, regulating trading and confidentiality of inside information for persons discharging
managerial responsibility (“PDMRs”) and persons closely associated with them which contains provisions
appropriate for a company whose shares are admitted to trading on the Official List. The Company intends to
take all reasonable steps to ensure compliance by PDMRs and any relevant employees with the terms of its share
dealing policy.
Evaluate board performance based on clear and relevant objectives, seeking
continuous improvement
All Board appointments have been made after consultation and detailed due diligence is carried out on all new
potential board candidates. The Board will consider using external advisers to review and evaluate the
effectiveness of the Board and Directors in future to supplement its own internal evaluation processes.
All Directors have disclosed any significant commitments to the Board and confirmed that they have sufficient
time to discharge their duties.
The Group’s Articles require that all Directors are submitted for election at the AGM following their first
appointment to the Board, and Directors for whom it is their third annual general meeting during their appointment,
are subject to retirement by rotation on an annual basis to refresh the Board, irrespective of performance.
The terms and conditions of appointment of Non-Executive Directors will be made available upon written request.
Seek to understand and meet shareholder needs and expectations
The Company is committed to engaging and communicating openly with its shareholders to ensure that its
strategy, business model and performance are clearly understood. All Board members have responsibility for
shareholder liaison, but queries are primarily delegated to the Company’s advisors in the first instance or the
Company’s Executive Chairman. Details of the Company’s advisors can be found on the Company’s website.
Copies of the annual and interim reports will be made available to all shareholders and copies may be downloaded
from the Company’s website.
Other Company information for shareholders is also available on the website.
The Company also engages with shareholders at its AGM each year which gives investors the opportunity to
enter into dialogue with the Board and for the Board to receive feedback and take action if and when necessary.
The results of the AGM are subsequently announced via RNS and published on the Company’s website.
Establish a strategy and business model which promote long-term value for
shareholders
The Company is developing pre-clinical next generation medicines focused on hard to treat cancers, with the aim
of generating optimal returns for our shareholders.
The investment strategy is to provide shareholders with an attractive total return achieved primarily through
capital appreciation.
26 Roquefort Therapeutics plc
Governance Report
continued
Take into account wider stakeholder and social responsibilities and their
implications for long-term success
The Board is aware that engaging with Roquefort Therapeutics’ stakeholders strengthens relationships, assists
the Board in making better business decisions and ultimately promotes the long-term success of Roquefort
Therapeutics plc. The Group’s stakeholders include shareholders, and other service providers, suppliers, auditors,
lenders, regulators, industry bodies and the surrounding communities of where its future investments will be
located. The Board as a whole are responsible for reviewing and monitoring the parties contracted to the Company,
including their service terms and conditions.
The Board is regularly updated on wider stakeholder views and issues concerning the portfolio both formally at
Board meetings and informally through ad hoc updates.
This Governance Report was approved by the Board and signed on its behalf by:
Stephen West
Executive Chairman
4 June 2023
Annual Report & Financial Statements 2022 27
Remuneration Committee Report
The Remuneration Committee presents its report for the year ended 31 December 2022.
Membership of the Remuneration Committee
During the period to 4 April 2022 the Remuneration Committee comprised of two Non-Executive Directors
Mark Rollins (chair) and Mark Freeman. On 4 April 2022 Mark Rollins resigned from the Board and the
Remuneration Committee. On 28 April 2022 Jean Duvall was appointed as chair of the Remuneration Committee,
with Dr Michael Stein acting as a temporary member during the interim period between the date of Mark Rollins
resignation and the appointment of Jean Duvall. On 16 September 2022 Mark Freeman resigned from the Board
and the Remuneration Committee; Dr Darrin Disley was appointed as chair of the Remuneration Committee; and
Jean Duvall remained a member of the Remuneration Committee.
During the year ended 31 December 2022, one formal meeting of the Remuneration Committee was held.
Subject to what appears below, no other third parties have provided advice that materially assisted the
Remuneration Committee during the year.
The items included in this report are unaudited unless otherwise stated.
Remuneration Committee’s main responsibilities
l The Remuneration Committee considers the remuneration policy, employment terms and remuneration of
the Board and advisors;
l The Remuneration Committee’s role is advisory in nature, and it makes recommendations to the Board on
the overall remuneration packages;
l The Remuneration Committee, when considering the remuneration packages of the Company’s Board, will
review the policies of comparable companies in the industry.
Report Approval
Resolution to approve this report will be proposed at the Annual General Meeting (“AGM”) of the Company. The
votes will have advisory status, will be in respect of the remuneration policy and overall remuneration packages
and will not be specific to individual levels of remuneration.
At the Company’s 2022 AGM a combined resolution to approve the directors’ remuneration report and
remuneration policy was passed with 100% votes in favour of the resolution. At the 2022 AGM, the Company did
not receive any views from shareholders regarding directors’ remuneration.
Remuneration policy
There was no external remuneration advice received by the Company during the year ended 31 December 2022
or 2021.
The remuneration policy of the Company is that each Director is entitled to a salary per annum from the date of
their appointment. The Executive Directors have entered into Service Agreements with the Company and continue
to be employed until terminated by the Company.
Non-Executive Directors fees are £24,000 each per annum, and are unchanged from last year.
Stephen West, as Executive Chairman, entered into a service agreement (the “Service Agreement”) with the Company
dated 26 February 2022 under which Mr West is employed until terminated by either party giving 6 months’ prior
written notice. Mr West received an annual salary of £120,000 until 15 September 2022 (pursuant to the terms of a
side letter dated 7 March 2022 amending the Service Agreement). On the successful acquisition of Oncogeni on
16September 2022, Mr West’s salary was increased to £139,000 (pursuant to a side letter dated 29 November 2022
amending the Service Agreement) and he became entitled to pension contributions of 10% of salary into a nominated
scheme from that date. Mr West is not entitled to any other benefits other than the reimbursement of his reasonable
expenses. In 2021 Mr West received a cash bonus of £10,000 to compensate him for work performed in 2020, prior
to entering into the Service Agreement. The Service Agreement is governed by English law.
28 Roquefort Therapeutics plc
Remuneration Committee Report
continued
Ajan Reginald, as Chief Executive Officer, entered into a service agreement with the Company dated
9 September 2022 (the “AR Service Agreement”). The AR Service Agreement was conditional on completion of
the acquisition of Oncogeni Ltd and will remain in force until terminated by either party giving not less than twelve
months’ written notice. Mr Reginald receives an annual salary of £278,000 plus any discretionary bonus which
the Company may choose to award in its sole and absolute discretion. Mr Reginald is entitled to pension
contributions of 10% of his salary into a nominated scheme. Mr Reginald is not entitled to any other benefits other
than the reimbursement of his reasonable expenses. For a period of twelve months following termination of
employment, Mr Reginald is subject to certain restrictive covenants preventing him from competing against the
Group, amongst other matters. The AR Service Agreement is governed by English law.
Sir Martin Evans, as Chief Scientific Officer, entered into a service agreement with the Company dated 9 September
2022 (the “ME Service Agreement”). The ME Service Agreement was conditional on completion of the acquisition
of Oncogeni Ltd and will remain in force until terminated by either party giving not less than three months’ notice.
Sir Evans will receive an annual salary of £100,000 for two days of work per week, plus any discretionary bonus
which the Company may choose to award in its sole and absolute discretion. Sir Evans is not entitled to any other
benefits other than the reimbursement of his reasonable expenses. For a period of twelve months following
termination of employment, Sir Evans is subject to certain restrictive covenants preventing him from competing
against the Group, amongst other matters. The ME Service Agreement is governed by English law.
The Company’s Remuneration Committee oversees decisions regarding the remuneration of the Board. The Board
believes that shares and warrants owned by Directors strengthens the link between their personal interests and
those of shareholders and is in line with the share dealing code adopted by the Company. Apart from the
Company’s share dealing code, there are no specific requirements or guidelines determined by the Remuneration
Committee for Directors to own shares in the Company.
Should the Company award share-based remuneration in the future, appropriate vesting and holding periods will
be determined by the Remuneration Committee.
Non-Executive Directors
The Company policy is that the Non-Executive Directors are expected to attend scheduled board meetings and
attend committee meetings as required.
Terms of appointment
The services of the Directors during the year ended 31 December 2022 were provided in accordance with their
appointment letters. Directors were expected to devote such time as was necessary for the proper performance
of their duties, but as a minimum they were expected to commit at least one day per month, which should include
attendance at all meetings of the Board and any sub-committees of the Board.
Year of
Director appointment
Stephen West 2020
Ajan Reginald 2022
Sir Martin Evans 2022
Dr Michael Stein 2021
Ms Jean Duvall 2022
Dr Simon Sinclair 2022
Dr Darrin Disley 2022
Mark Rollins (resigned 4 April 2022) 2020
Mark Freeman (resigned 16 September 2022) 2021
Annual Report & Financial Statements 2022 29
Remuneration Committee Report
continued
Directors’ emoluments and compensation (audited)
Set out below are the emoluments of the Directors who served in the year ended 31 December 2022 (GBP):
Annual
Bonus
and Long
Salary and Taxable Term Pension Share Based
Name of Director Fees Benefits Benefits Related Payment Total
Stephen West 114,251 – – 4,054 – 118,305
Ajan Reginald 81,269 – – 8,108 – 89,377
Sir Martin Evans 29,807 – – – – 29,807
Dr Michael Stein 24,354 – – – – 24,354
Ms Jean Duvall 17,753 – – – 2,808 20,561
Dr Simon Sinclair 16,738 – – – 2,808 19,546
Dr Darren Disley 7,015 – – – – 7,015
Mark Rollins – – – – – –
Mark Freeman 17,505 – – – 17,505
Total 308,692 – – 12,162 5,616 326,470
Set out below are the emoluments of the Directors who served in the period ended 31 December 2021 (GBP):
Annual
Bonus
and Long Pension
Salary and Taxable Term Related Share Based
Name of Director Fees Benefits Benefits Benefits Payment Total
Stephen West 18,645 – 10,000 – 132,180 160,825
Glenn Whiddon 6,968 – – – – 6,968
Mark Rollins 9,677 – – – 7,808 17,485
Dr Michael Stein 9,323 – – – 22,449 31,772
Mark Freeman 2,688 – – – 15,616 18,304
Total 47,301 – 10,000 – 178,053 235,354
Directors warrants (audited)
Details of warrants in the Company held by Directors who served during the year are set out below:
Vested but
Exercised unexercised
As at 1 Granted or lapsed As at 31 at 31 Final
Name of January during during December December Exercise Date of Vesting
Director 2022 the year the year 2022 2022 price grant date
Stephen 3,000,000 – – 3,000,000 3,000,000 £0.10 25/11/2020 21/12/2021
West* 500,000 – – 500,000 500,000 £0.10 22/03/2021 22/03/2021
3,000,000 – – 3,000,000 3,000,000 £0.10 13/10/2021 13/10/2021
1,000,000 – – 1,000,000 333,333 £0.15 13/10/2021 21/12/2024
7,500,000 – – 7,500,000 6,833,333
Ms Jean – 300,000 – 300,000 – £0.15 22/06/2022 28/04/2024
Duval – 300,000 – 300,000 –
Dr Simon – 300,000 – 300,000 – £0.15 22/06/2022 28/04/2024
Sinclair – 300,000 – 300,000 –
Mark 3,000,000 – – 3,000,000 3,000,000 £0.10 25/11/2020 21/12/2021
Rollins 500,000 – – 500,000 500,000 £0.10 22/03/2021 22/03/2021
250,000 – – 250,000 83,333 £0.15 13/10/2021 21/12/2024
3,750,000 – – 3,750,000 3,583,333
Dr Michael 750,000 – – 750,000 750,000 £0.05 22/03/2021 21/12/2021
Stein 750,000 – – 750,000 750,000 £0.10 22/03/2021 21/12/2021
500,000 – – 500,000 166,667 £0.15 13/10/2021 21/12/2024
2,000,000 – – 2,000,000 1,666,667
Mark 500,000 – – 500,000 166,667 £0.15 13/10/2021 21/12/2024
Freeman 500,000 – – 500,000 166,667
*held by Cresthaven Investments Pty Ltd ATF The Bellini Trust – an entity associated with S West
30 Roquefort Therapeutics plc
Details of warrants in the Company held by Directors who served during the year ended 31 December 2021 are
set out below:
Vested but
Exercised unexercised
As at 1 Granted or lapsed As at 31 at 31
Name of January during during December December Exercise Date of Vesting
Director 2021 the year the year 2021 2022 price grant date
Stephen 3,000,000 – – 3,000,000 3,000,000 £0.10 25/11/2020 21/12/2021
West* – 500,000 – 500,000 500,000 £0.10 22/03/2021 22/03/2021
– 3,000,000 – 3,000,000 3,000,000 £0.10 13/10/2021 13/10/2021
– 1,000,000 – 1,000,000 – £0.15 13/10/2021 21/12/2024
3,000,000 4,500,000 – 7,500,000 6,500,000
Mark 3,000,000 – – 3,000,000 3,000,000 £0.10 25/11/2020 21/12/2021
Rollins – 500,000 – 500,000 500,000 £0.10 22/03/2021 22/03/2021
– 250,000 – 250,000 – £0.15 13/10/2021 21/12/2024
3,000,000 750,000 – 3,750,000 3,500,000
Dr Michael – 750,000 – 750,000 750,000 £0.05 22/03/2021 21/12/2021
Stein – 750,000 – 750,000 750,000 £0.10 22/03/2021 21/12/2021
– 500,000 – 500,000 – £0.15 13/10/2021 21/12/2024
– 2,000,000 – 2,000,000 1,500,000
Mark – 500,000 – 500,000 – £0.15 13/10/2021 21/12/2024
Freeman – 500,000 – 500,000 –
*held by Cresthaven Investments Pty Ltd ATF The Bellini Trust – an entity associated with S West
Pension contributions (audited)
The Company does not currently have any pension plans for any of the Directors. It pays any pension amounts
due in relation to their remuneration into funds nominated by them.
The Company has not paid out any excess retirement benefits to any Directors or past Directors.
Payments to past directors (audited)
The Company has not paid any compensation to past Directors.
Payments for loss of office (audited)
No payments were made for loss of office during the year.
The Committee will honour contractual entitlements. Service contracts do not contain liquidated damages
clauses. If a contract is to be terminated, the Committee will determine such mitigation as it considers fair and
reasonable in each case. There is no agreement between the Company and its Executive Directors or employees,
providing for compensation for loss of office or employment that occurs because of a takeover bid.
The Committee reserves the right to make additional payments where such payments are made in good faith in
discharge of an existing legal obligation (or by way of damages for breach of such an obligation); or by way of
settlement or compromise of any claim arising in connection with the termination of an Executive Director’s office
or employment.
Remuneration Committee Report
continued
Annual Report & Financial Statements 2022 31
UK Remuneration percentage changes
The Executive Chairman, Stephen West was awarded total fees of £18,645 in the period ended 31 December 2021.
Fees were paid from 1 April 2021, a nine month period. Mr West’s fees were £24,000 per annum until the
acquisition of Lyramid on 21 December 2021, when his fees increased 100% to £48,000.
In the year ended 31 December 2022, Stephen West was awarded total fees of £114,251. Mr West’s fees have
increased twice during 2022 to reflect the growth of the Company and the extra time commitment required from
Mr West. On 26 February 2022 Mr West’s fees increased by 150% to £120,000. Following the acquisition of
Oncogeni Mr West’s fees increased by a further 15.8% to £139,000.
The CEO, Ajan Reginald and the Chief Scientific Officer, Sir Martin Evans, were appointed in 2022. These are
newroles.
All Non-Executive Directors were paid £12,000 until 21 December 2021, when on the acquisition of Lyramid their
fees increased 100% to £24,000 per annum. This doubling affected three Non-Executives, Dr Michael Stein,
MarkRollins (resigned 4 April 2022), and Mark Freeman (resigned 16 September 2022). All other Non-Executive
Directors have been appointed in 2022, and there has been no further change to their remuneration in the year.
UK 10-year performance graph
The Directors have considered the requirement for a UK 10-year performance graph comparing the Company’s
Total Shareholder Return with that of a comparable indicator. The Directors do not currently consider that including
the graph will be meaningful because the Company only listed in 2021, is not paying dividends, is currently
incurring losses as it gains scale, and its focus during the year ended 31 December 2022 was to integrate the
acquisition of Oncogeni. In addition, and as mentioned above, the remuneration of Directors was not linked to
performance and we therefore do not consider the inclusion of this graph to be useful to shareholders at the
current time. The Directors will review the inclusion of this graph for future reports.
UK 10-year CEO table and UK percentage change table
The Company has employed a CEO from 16 September 2022 therefore the Directors do not currently consider
that including such a table would be meaningful. The Directors will review the inclusion of this table for future
reports. The CEO’s remuneration was agreed with reference to the advice of a third-party recruitment company.
They provided evidence of salaries in similar organisations, giving a benchmark for the salary of the new CEO.
Relative importance of spend on pay
The table below illustrates the year-on-year change in total remuneration compared to distributions to
shareholders and operational cash flow for the financial periods ended 31 December 2022 and 2021:
Total directors
Distributions to and employee Operational
shareholders pay cash outflow
£ £ £
Year ended 31 December 2022 – 572,538 1,577,476
Period ended 31 December 2021 – 300,124 516,833
Total employee pay includes wages and salaries, social security costs and pension cost for employees in
continuing operations. Further details on Employee remuneration are provided in note 6. Operational cash outflow
has been shown in the table above as cash flow monitoring and forecasting is an important consideration for the
Remuneration Committee and Board of Directors when determining cash-based remuneration for directors and
employees.
Remuneration Committee Report
continued
32 Roquefort Therapeutics plc
UK Directors’ shares (audited)
The interests of the Directors who served during the year in the share capital of the Company at 31 December
2022 and at the date of this report has been set out in the Directors’ Report on pages 9 to 12.
Other matters
The Company does not currently have any other annual or long-term incentive schemes in place for any of the
Directors and as such there are no disclosures in this respect.
Approved on behalf of the Board of Directors by:
Dr Darrin Disley
Chair of the Remuneration Committee
4 June 2023
Remuneration Committee Report
continued
Annual Report & Financial Statements 2022 33
Audit Committee Report
The Audit Committee comprised of two Non-Executive Directors Mark Freeman as chair and Dr. Michael Stein
until 16 September 2022 when Mark Freeman resigned from the Board and the Audit Committee. On this date
JeanDuvall was appointed as chair of the Audit Committee, and Dr. Michael Stein remained a member of the
Committee.
The Audit Committee oversees the Company’s financial reporting and internal controls and provides a formal
reporting link with the external auditors. The ultimate responsibility for reviewing and approving the annual report
and financial statements and the half-yearly report remains with the Board.
Main Responsibilities
The Audit Committee acts as a preparatory body for discharging the Board’s responsibilities in a wide range of
financial matters by:
l monitoring the integrity of the financial statements and formal announcements relating to the Company’s
financial performance;
l reviewing significant financial reporting issues, accounting policies and disclosures in financial reports,
which are considered to be in accordance with the key audit matters identified by the external auditors;
l overseeing that an effective system of internal control and risk management systems are maintained;
l ensuring that an effective whistle-blowing, anti-fraud and bribery procedures are in place;
l overseeing the Board’s relationship with the external auditor and, where appropriate, the selection of new
external auditors;
l monitoring the statutory audit of the annual financial statements, in particular, its performance, taking into
account any findings and conclusions by the competent authority;
l approving non-audit services provided by the external auditor, or any other accounting firm, ensuring the
independence and objectivity of the external auditors is safeguarded when appointing them to conduct
non-audit services; and
l ensuring compliance with legal requirements, accounting standards and the Listing Rules and the Disclosure
and Transparency Rules.
Governance
Good practice suggests that at least one member of the Audit Committee has recent and relevant financial
experience. The Audit Committee’s previous chair, Mark Freeman, is a Chartered Accountant with over 25 years’
experience in corporate finance and the public markets. The Audit Committee’s current chair, Jean Duvall, has
significant business and commercial experience, including with public companies. The Board is satisfied that the
Audit Committee has recent and relevant financial experience.
Members of the Audit Committee are appointed by the Board and whilst warrant holders, the Company believes
they are considered to be independent in both character and judgement.
The Company’s external auditor is BDO LLP (2021: Jeffreys Henry LLP) and the Audit Committee will closely monitor
the level of audit and non-audit services they provide to the Company.
34 Roquefort Therapeutics plc
Audit Committee Report
continued
Meetings
For the year to 31 December 2022 the Board has met with the auditors on two occasions.
The key work undertaken by the Audit Committee is as follows:
l interview of external auditors and recommendation to the Board;
l review of audit planning and update on relevant accounting developments;
l consideration and approval of the risk management framework, appropriateness of key performance
indicators;
l consideration and review of full-year results;
l review of the effectiveness of the Audit Committee;
l review of internal controls; and
l considered whether an internal audit function is required and confirmed it is not considered necessary given
the present size of the Company.
The Audit Committee has primary responsibility for making a recommendation on the appointment, reappointment
or removal of the external auditor.
The Audit Committee noted the level of prior period adjustments, as described in respect of the Group and
Company cashflow statements, the Group and Company statements of financial position, the Group and Company
statements of changes in equity, and the notes to the Group and company financial statements for the year ended
31 December 2021. Further control processes will be implemented by the finance department, to assure the
Committee that the Group’s financial statements prepared for audit are free from material misstatement.
External auditor
The Company’s external auditor is BDO. The external auditor has unrestricted access to the Audit Committee
chair. The Committee is satisfied that BDO has adequate policies and safeguards in place to ensure that auditor
objectivity and independence are maintained.
The external auditors report to the Audit Committee annually on their independence from the Company. In
accordance with professional standards, the partner responsible for the audit is changed every five years. The
current auditor, BDO was first appointed by the Company in 2023, and therefore the current partner is due to rotate
off the engagement after completing the audit for the year ended 31 December 2026. Having assessed the
performance objectivity and independence of the auditors, the Committee will be recommending the
reappointment of BDO as auditors to the Group at the 2023 Annual General Meeting.
Approved on behalf of the Board of Directors by:
Ms Jean Duvall
Chair of the Audit Committee
4 June 2023
Annual Report & Financial Statements 2022 35
Nomination Committee Report
The Nomination Committee comprised of two Non-Executive Directors Dr Michael Stein (as chair) and
Mark Freeman during the period to 28 April 2022. On 28 April 2022 Mark Freeman resigned from, and
SimonSinclair was appointed to, the Nomination Committee. The committee considers potential candidates for
appointment to the Company’s Board who maintain the highest standards of corporate governance and have
sufficient time to commit to the role.
Nomination committee evaluation
The Nomination Committee evaluates the composition, skills, and diversity of the Board and its committees and
identifies a requirement for a Board appointment.
Identify suitable candidates
The Nomination Committee undertakes a review of each candidate and their experience in accordance with the
Company’s ‘director’s profile’ and suitable candidates are identified.
For the appointment of a Chairman, the Nomination Committee will prepare a job specification, including an
assessment of the time commitment expected, recognising the need for availability in the event of crises.
Nomination committee recommendation
Following interviews with a candidate conducted by the Chairman, and other members of the Board, the
Nomination Committee makes a recommendation on a preferred candidate to the Board. Ms Duvall and Dr Sinclair
were appointed as non-executive directors of the Company on 5 April 2022 and 20 April 2022, respectively, after
following this process.
Upon completion of the acquisition of Oncogeni on 16 September 2022, Mr Reginald and Prof. Evans were
appointed as executive directors of the Company (Chief Executive Officer and Chief Scientific Officer respectively),
and Dr Disley was appointed a non-executive director of the Company. Prior to their appointment as directors of
the Company, Mr Reginald, Prof. Evans and Dr Disley were interviewed by the Chairman and members of the
Nomination Committee, with the Nomination Committee subsequently recommending their appointments to the
Board.
Due diligence
After a candidate has been recommended to the Board by the Nomination Committee, the company secretary
undertakes appropriate background checks on a candidate. The Board of directors meets any candidate
recommended by the Nomination Committee and the candidate is given an opportunity to make a presentation
to the Board prior to deciding on their appointment.
Board appointment
The Board formally approves a candidate’s appointment to the Board.
Approach to Diversity
The Nomination Committee believes in the benefits of diversity, including the need for diversity in order to
effectively represent shareholders’ interests. This diversity is not restricted to gender but also includes geographic
location, nationality, skills, age, educational and professional background. The Board’s policy remains that selection
should be based on the best person for the role.
On behalf of the Nomination Committee
Dr Michael Stein
Chair of the Nomination Committee
4 June 2023
36 Roquefort Therapeutics plc
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
Opinion on the financial statements
In our opinion:
l the financial statements give a true and fair view of the state of the Group’s and of the Parent Company’s
affairs as at 31 December 2022 and of the Group’s loss for the year then ended;
l the Group financial statements have been properly prepared in accordance with UK adopted international
accounting standards;
l the Parent Company financial statements have been properly prepared in accordance with UK adopted
international accounting standards and as applied in accordance with the provisions of the Companies Act
2006; and
l the financial statements have been prepared in accordance with the requirements of the Companies Act
2006.
We have audited the financial statements of Roquefort Therapeutics Plc (the ‘Parent Company’) and its
subsidiaries (the ‘Group’) for the year ended 31 December 2022 which comprise the Consolidated statement of
comprehensive income, the Consolidated statement of financial position, the Statement of financial position, the
Consolidated statement of changes in Equity, the Statement of changes in equity, the Consolidated statement of
cash flows, the Statement of cash flows and notes to the financial statements, including a summary of significant
accounting policies. The financial reporting framework that has been applied in their preparation is applicable law
and UK adopted international accounting standards and as regards the Parent Company financial statements,
as applied in accordance with the provisions of the Companies Act 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable
law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit
of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient
and appropriate to provide a basis for our opinion. Our audit opinion is consistent with the additional report to the
audit committee.
Independence
Following the recommendation of the audit committee, we were appointed by the Board of Directors on 13 January
2023 to audit the financial statements for the year ended 31 December 2022 and subsequent financial periods.
The period of total uninterrupted engagement is 1 year, covering the year ended 31 December 2022. We are
independent of the Group and the Parent Company in accordance with the ethical requirements that are relevant
to our audit of the financial statements in the UK, including the FRC’s Ethical Standard as applied to listed public
interest entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.
The non-audit services prohibited by that standard were not provided to the Group or the Parent Company.
Material uncertainty related to going concern
We draw attention to Note 3b of the financial statements, which indicates the Directors’ assessment that the
Group is dependent on raising further funds, in order to meet its forecast cash flow requirements for the going
concern period being at least 12 months from the date of approval of these financial statements. As stated in
Note 3b, these events or conditions indicate that a material uncertainty exists that may cast significant doubt on
the Group’s and Parent Company’s ability to continue as a going concern. Our opinion is not modified in respect
of this matter.
In auditing the financial statements, we have concluded that the Directors’ use of the going concern basis of
accounting in the preparation of the financial statements is appropriate.
Annual Report & Financial Statements 2022 37
We considered the ability of the Group and the Parent Company to continue as a going concern to be a key audit
matter based on our assessment of the significance of the risk and the effect on our audit strategy.
Our evaluation of the Directors’ assessment of the Group and the Parent Company’s ability to continue to adopt
the going concern basis of accounting and procedures in response to the key audit matter included:
We obtained the Directors’ going concern assessment, including the detailed forecast for the period ending 31
December 2024 and:
l Evaluated the Directors’ method of assessment, including the relevance and reliability of underlying data
used to make the assessment, and whether assumptions and changes to assumptions from prior years are
appropriate and consistent with each other.
l Tested the assumptions used, including the level of forecast research and development (R&D) costs and
general and administrative expenditure by corroborating a sample of costs to supporting evidence, including
third party cost estimates for development projects.
l Determined through inspection and testing of the methodology and calculations that the methods utilised
were appropriate to be able to make an assessment for the Group taking into consideration the nature of
the Group’s cost base and cash inflows.
l We evaluated the Directors’ sensitivity analysis for reasonably possible changes in the cost base, tested the
arithmetic accuracy of this analysis and challenged the assumptions applied.
l We enquired of management regarding fundraising and out -licensing activities to date, including review of
correspondence with potential partners.
l We evaluated the period assessed by the Directors to determine that they had considered a period of at
least 12 months from the date of approval of the financial statements. We also enquired whether the
Directors had considered and identified any events or conditions that may exist beyond that period; examined
board meeting minutes and press releases for any such events or conditions.
We assessed the adequacy and appropriateness of disclosures in the financial statements regarding the going
concern assessment.
Our responsibilities and the responsibilities of the Directors with respect to going concern are described in the
relevant sections of this report.
Other matter
The corresponding figures presented in the Parent Company’s statement of cash flows are unaudited.
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
continued
38 Roquefort Therapeutics plc
Overview
Coverage 100% of Group loss before tax
100% of Group total assets
Key audit matters 2022
4
4
4
Materiality Group financial statements as a whole
£76,300 based on 4.9% of loss before tax
An overview of the scope of our audit
Our Group audit was scoped by obtaining an understanding of the Group and its environment, including the
Group’s system of internal control, and assessing the risks of material misstatement in the financial statements.
We also addressed the risk of management override of internal controls, including assessing whether there was
evidence of bias by the Directors that may have represented a risk of material misstatement.
At 31 December 2022, the Group comprised of the Parent Company; one trading UK company (Oncogeni Ltd),
one trading Australian company (Lyramid Pty Ltd) and two dormant companies.
The Parent Company and the Australian trading company (Lyramid Pty Ltd) were deemed to be the significant
components for the Group and were subject to full scope audit procedures. For the non-significant UK trading
company, specified audit procedures were performed over material balances. The financial information of the
remaining non-significant components were subject to analytical review procedures The audit procedures over
all these entities were carried out by the group audit team for the purposes of this opinion.
Climate change
Our work on the assessment of potential impacts on climate-related risks on the Group’s operations and financial
statements included:
l Enquiries and challenge of management to understand the actions they have taken to identify climate-related
risks and their potential impacts on the financial statements and adequately disclose climate-related risks
within the annual report;
l Our own qualitative risk assessment taking into consideration the sector in which the Group operates and
how climate change affects this particular sector; and
l Review of the minutes of Board and Audit Committee meetings.
We challenged the extent to which climate-related considerations have been reflected, where appropriate, in the
Directors’ going concern assessment.
We also assessed the consistency of management’s disclosures included as ‘Other Information’ with the financial
statements and with our knowledge obtained from the audit.
Based on our risk assessment procedures, we did not identify there to be any Key Audit Matters materially
impacted by climate-related risks.
Going concern
Impairment review of carrying value of
goodwill and intangible assets &
Impairment review of carrying value of
investments in subsidiaries (Parent
Company statement of financial position)
Oncogeni acquisition accounting
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
continued
Annual Report & Financial Statements 2022 39
Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of
the financial statements of the current period and include the most significant assessed risks of material
misstatement (whether or not due to fraud) that we identified, including those which had the greatest effect on:
the overall audit strategy, the allocation of resources in the audit, and directing the efforts of the engagement
team. These matters were addressed in the context of our audit of the financial statements as a whole, and in
forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter
set out in the Material uncertainty related to going concern section of our report, we have determined the matters
below to be the key audit matters to be communicated in our report.
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
continued
Key audit matter How the scope of our audit addressed the key audit
matter
Impairment review of
carrying value of
goodwill and intangible
assets
Goodwill of £281,911
(2021 - £281,911); in-
progress R&D of
£5,061,594 (2021 -
£1,199,619); accounting
policy note 3h and
note12.
Impairment review of
carrying value of
investments in
subsidiaries (Parent
Company statement of
financial position)
Investments in
subsidiaries of
£4,874,774 (2021 –
£1,015,695); accounting
policy note 3h and
note13.
The Group has significant
intangible assets arising
from a business
acquisition and an asset
acquisition.
The Parent Company
holds significant
investments in
subsidiaries arising from
the same two acquisition
transactions.
Management’s
determination of
recoverable values of the
goodwill, identifiable
intangible assets
(representing in-progress
research and
development) and
investments in
subsidiaries is based on
fair value less costs to
sell and includes
management’s
judgements over the
selection of relevant
transactions of oncology
drug candidates at a
similar stage of
development, to provide
benchmark values.
These assumptions are
subjective in nature.
As there are judgemental
areas within the
assessment of the
carrying values, a
significant risk was
identified which we
deemed to be a key audit
matter.
Our audit procedures included:
l We assessed whether management’s approach for
assessing the impairment of its intangible assets
and investments was appropriate, and if the
assessment complied with the requirements of the
applicable accounting standards.
l We obtained an understanding of the research and
development activities for each intangible asset
and investment to assess and evaluate the
existence of any internal or external indicators of
impairment, by inspecting minutes of meetings,
investor information, analyst notes and R&D
investor presentation information;
l With the assistance of our internal valuation
experts, we reviewed the comparator transactions
identified by management’s valuation experts, and
valuations thereof, and corroborated a sample
back to publicly available supporting
documentation. Using our industry knowledge, we
assessed whether the comparator transactions
were appropriately selected based on disease area
and stage of development.
l We considered other data supporting the original
price paid for intangible assets and investments,
including research costs incurred and spin-out
transaction valuations.
Key observations
Based on the procedures performed we consider that
the assumptions made by management in their
carrying value assessments are reasonable.
40 Roquefort Therapeutics plc
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
continued
Key audit matter How the scope of our audit addressed the key audit
matter
Oncogeni acquisition
accounting
Intangible asset –
£3,880,985 (Accounting
policy note 3h, notes 4
and12)
Management has applied
the concentration test
under IFRS3 to the
acquisition of Oncogeni
Limited, and determined
to account for the
transaction as an asset
acquisition under IAS38.
The directly attributable
issuance costs have been
included in the asset
acquisition cost.
As there is management
judgement regarding the
application of the
concentration test and
the determination of the
cost of the asset
acquisition, a significant
risk was identified which
we deemed to be a key
audit matter.
Our audit procedures included:
l We reviewed management’s IFRS3 concentration
test, for appropriateness based on our
understanding of the acquisition, the underlying
assets and liabilities acquired and the nature of the
in-progress research and development programs,
through review of the acquisition agreement, the
acquisition prospectus, the investor presentation
and inquiries of management, and determined
whether it was appropriate to account for the
transaction as an asset acquisition under IAS38.
l We reviewed the nature of costs directly incurred
in association with the acquisition, verified a
sample to supporting documentation, and
confirmed their accounting treatment as part of the
cost of the asset acquisition in accordance with the
requirements of IAS38.
Key observations
Based on the procedures performed, we consider that
management’s use of the asset acquisition accounting
treatment and assessment of directly related
acquisition costs are reasonable.
Our application of materiality
We apply the concept of materiality both in planning and performing our audit, and in evaluating the effect of
misstatements. We consider materiality to be the magnitude by which misstatements, including omissions,
could influence the economic decisions of reasonable users that are taken on the basis of the financial
statements.
In order to reduce to an appropriately low level the probability that any misstatements exceed materiality, we
use a lower materiality level, performance materiality, to determine the extent of testing needed. Importantly,
misstatements below these levels will not necessarily be evaluated as immaterial as we also take account of
the nature of identified misstatements, and the particular circumstances of their occurrence, when evaluating
their effect on the financial statements as a whole.
Annual Report & Financial Statements 2022 41
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
continued
Based on our professional judgement, we determined materiality for the financial statements as a whole and
performance materiality as follows:
Group financial Parent company
statements financial statements
2022 2022
£ £
Materiality 76,300 68,600
Basis for determining materiality 4.9% of Loss before tax 90% of group materiality
Performance materiality 38,150 34,300
50% of materiality 50% of materiality
Component materiality
For the purposes of our Group audit opinion, we set materiality for the significant component of the Group, apart
from the Parent Company whose materiality is set out above, based on a percentage of 37% of Group materiality
dependent on the size and our assessment of the risk of material misstatement of that component. Component
materiality was £28,000. In the audit of the component, we further applied a performance materiality level of 50%
of the component materiality to our testing to ensure that the risk of errors exceeding component materiality was
appropriately mitigated.
Reporting threshold
We agreed with the Audit Committee that we would report to them all individual audit differences in excess of
£2,300. We also agreed to report differences below this threshold that, in our view, warranted reporting on
qualitative grounds.
Other information
The directors are responsible for the other information. The other information comprises the information included
in the Annual Report and Financial Statements other than the financial statements and our auditor’s report
thereon. Our opinion on the financial statements does not cover the other information and, except to the extent
otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our
responsibility is to read the other information and, in doing so, consider whether the other information is materially
inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise
appears to be materially misstated. If we identify such material inconsistencies or apparent material
misstatements, we are required to determine whether this gives rise to a material misstatement in the financial
Rationale for the benchmark applied Loss before tax is considered
the most appropriate measure
in assessing the performance of
the Group given that the primary
focus of the users relates to
overall expenditure (including
research and development
costs) to progress development
of drug candidates.
Materiality was capped at 90%
Group materiality given the
assessment of the components’
aggregation risk.
Basis for determining performance
materiality
Performance materiality was set
taking into consideration our risk
assessment and the fact that
this is our first year as auditors
of the Group.
Performance materiality was set
taking into consideration our risk
assessment and the fact that
this is our first year as auditors
of the Parent Company.
Rationale for the percentage applied
for performance materiality
42 Roquefort Therapeutics plc
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
continued
statements themselves. If, based on the work we have performed, we conclude that there is a material
misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Other Companies Act 2006 reporting
Based on the responsibilities described below and our work performed during the course of the audit, we are
required by the Companies Act 2006 and ISAs (UK) to report on certain opinions and matters as described below.
Responsibilities of Directors
As explained more fully in the Statement of Directors’ Responsibilities, the Directors are responsible for the
preparation of the financial statements and for being satisfied that they give a true and fair view, and for such
internal control as the Directors determine is necessary to enable the preparation of financial statements that are
free from material misstatement, whether due to fraud or error.
Strategic report and Directors’
report
In our opinion, based on the work undertaken in the course of the audit:
l the information given in the Strategic report and the Directors’
report for the financial year for which the financial statements
are prepared is consistent with the financial statements; and
l the Strategic report and the Directors’ report have been
prepared in accordance with applicable legal requirements.
In the light of the knowledge and understanding of the Group and
Parent Company and its environment obtained in the course of the
audit, we have not identified material misstatements in the Strategic
report or the Directors’ report.
Directors’ remuneration In our opinion, the part of the Directors’ remuneration report to be
audited has been properly prepared in accordance with the Companies
Act 2006.
Matters on which we are
required to report by exception
We have nothing to report in respect of the following matters in relation
to which the Companies Act 2006 requires us to report to you if, in our
opinion:
l adequate accounting records have not been kept by the Parent
Company, or returns adequate for our audit have not been
received from branches not visited by us; or
l the Parent Company financial statements and the part of the
Directors’ remuneration report to be audited are not in
agreement with the accounting records and returns; or
l certain disclosures of Directors’ remuneration specified by law
are not made; or
l we have not received all the information and explanations we
require for our audit.
Annual Report & Financial Statements 2022 43
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
continued
In preparing the financial statements, the Directors are responsible for assessing the Group’s and the Parent
Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and
using the going concern basis of accounting unless the Directors either intend to liquidate the Group or the Parent
Company or to cease operations, or have no realistic alternative but to do so.
Auditor’s responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free
from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our
opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in
accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise
from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be
expected to influence the economic decisions of users taken on the basis of these financial statements.
Extent to which the audit was capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures
in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities,
including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is
detailed below:
Non-compliance with laws and regulations
Based on:
l Our understanding of the Group and the industry in which it operates;
l Discussion with management, those charged with governance and the Audit Committee; and
l Obtaining and understanding of the Group’s policies and procedures regarding compliance with laws and
regulations, we considered the significant laws and regulations to be the accounting framework (UK-adopted
international accounting standards); the Companies Act 2006; Listing Rules; and relevant tax legislation.
The Group is also subject to laws and regulations where the consequence of non-compliance could have a
material effect on the amount or disclosures in the financial statements, for example through the imposition of
fines or litigations. We identified such laws and regulations to be the requirements for developing regulated
therapeutic products.
Our procedures in respect of the above included:
l Review of minutes of meeting of those charged with governance for any instances of non-compliance with
laws and regulations;
l Review of correspondence with regulatory and tax authorities for any instances of non-compliance with
laws and regulations;
l Review of financial statement disclosures and agreeing to supporting documentation; and
l Review of legal expenditure accounts to understand the nature of expenditure incurred.
44 Roquefort Therapeutics plc
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
continued
Fraud
We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk
assessment procedures included:
l Enquiry with management, those charged with governance and the Audit Committee regarding any known
or suspected instances of fraud;
l Obtaining an understanding of the Group’s policies and procedures relating to:
o Detecting and responding to the risks of fraud; and
o Internal controls established to mitigate risks related to fraud.
l Review of minutes of meeting of those charged with governance for any known or suspected instances of
fraud;
l Discussion amongst the engagement team as to how and where fraud might occur in the financial
statements;
l Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks
of material misstatement due to fraud; and
l Considering remuneration incentive schemes and performance targets and the related financial statement
areas impacted by these.
Based on our risk assessment, we considered the areas most susceptible to fraud to be management override of
controls, specifically in relation to management bias and the judgements involved in accounting estimates (such
as impairment review valuation of goodwill, intangible assets and investments; and valuation of provision for
deferred contingent consideration).
Our procedures in respect of the above included:
l Testing a sample of journal entries throughout the year, which met a defined risk criteria, by inquiry and
agreeing to supporting documentation; and
o Assessing significant estimates made by management for potential bias, in particular the estimates
regarding the goodwill, intangible assets and investments impairment reviews (refer to key audit matter
section above).
o Inquiry of management regarding confirmation that future market capitalisation increases above the
level required for deferred contingent consideration to be payable could not be reliably estimated, and
therefore the fair value is continued to be estimated as nil. Our procedures included confirmation to
publicly available market price information, that the Group’s market capitalisation had not reached the
level required for any deferred consideration to be payable, prior to the date of this report.
We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team
members who were all deemed to have appropriate competence and capabilities and remained alert to any
indications of fraud or non-compliance with laws and regulations throughout the audit.
Our audit procedures were designed to respond to risks of material misstatement in the financial statements,
recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not
detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery,
misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and
the further removed non-compliance with laws and regulations is from the events and transactions reflected in
the financial statements, the less likely we are to become aware of it.
Annual Report & Financial Statements 2022 45
Independent Auditors’ Report to the Members of
Roquefort Therapeutics plc
continued
A further description of our responsibilities is available on the Financial Reporting Council’s website at:
www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
Use of our report
This report is made solely to the Parent Company’s members, as a body, in accordance with Chapter 3 of Part 16
of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Parent Company’s
members those matters we are required to state to them in an auditor’s report and for no other purpose. To the
fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Parent
Company and the Parent Company’s members as a body, for our audit work, for this report, or for the opinions
we have formed.
Ian Oliver (Senior Statutory Auditor)
For and on behalf of BDO LLP, Statutory Auditor
Reading, UK
4 June 2023
BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).
46 Roquefort Therapeutics plc
Consolidated Statement of Comprehensive Income
Year ended Period ended
31 December 31 December
2022 2021
Note £ £
Revenue 7 – 719
Other income – 130
Cost of goods sold – (10,069 )
Administrative expenses 9 (1,306,561 ) (252,392 )
Costs associated with the IPO 9 – (182,053 )
Share based payments - directors and senior managers 9 (8,427 ) (248,326 )
Costs associated with acquisition of subsidiary 9 – (224,744 )
Research and development expenditure 9 (319,315 ) (698 )
Operating loss & loss before taxation (1,634,303 ) (917,433 )
Taxation 10 18,886 –
Loss for the period (1,615,417 ) (917,433 )
Other comprehensive (loss) income 8 (14,989 ) 624
Total comprehensive loss for the period attributable to equity
holders of the parent (1,630,406 ) (916,809 )
Loss per share (basic and diluted) attributable
to the equity holders (pence) 11 (1.56 ) (3.71 )
The notes to the financial statements form an integral part of these financial statements.
Annual Report & Financial Statements 2022 47
Restated
As at As at
31 December 31 December
2022 2021
Note £ £
Assets
Non-current assets
Intangible assets 12 5,343,505 1,481,530
Total non-current assets 5,343,505 1,481,530
Current assets
Trade and other receivables 14 101,738 2,178,783
Cash and cash equivalents 15 2,322,974 899,721
Total current assets 2,424,712 3,078,504
Total assets 7,768,217 4,560,034
Equity and liabilities
Equity attributable to shareholders
Share capital 18 1,291,500 719,000
Share premium 18 4,403,094 3,460,595
Share based payments reserve 19 375,135 366,708
Merger relief reserve
1
20 3,700,000 450,000
Retained deficit (2,548,728 ) (914,321 )
Currency translation reserve (14,365 ) 624
Total equity 7,206,636 4,082,606
Liabilities
Non-Current liabilities
Deferred tax liabilities 17 281,911 281,911
Current liabilities
Trade and other payables 16 279,670 195,517
Total liabilities 561,581 477,428
Total equity and liabilities 7,768,217 4,560,034
1
In the prior period Merger relief reserve was not applied for the consideration shares issued for the acquisition of Lyramid, in error. £450,000 previously recorded as
share premium has been reclassified into a merger relief reserve in accordance with the UK Companies Act. There has been no impact to the prior period’s
consolidated statement of comprehensive income or net asset position.
The notes to the financial statements form an integral part of these financial statements.
This report was approved by the Board and authorised for issue on 4 June 2023 and signed on its behalf by:
Stephen West
Executive Chairman
Company Registration Number: 12819145
Consolidated Statement of Financial Position
48 Roquefort Therapeutics plc
Restated
As at As at
31 December 31 December
2022 2021
Note £ £
Assets
Non-current assets
Investments 13 4,874,774 1,015,695
Intercompany receivables 451,622 132,800
Total non-current assets 5,326,396 1,148,495
Current assets
Trade and other receivables 14 64,309 2,136,224
Cash and cash equivalents 15 2,274,478 857,614
Total current assets 2,338,787 2,993,838
Total assets 7,665,183 4,142,333
Equity and liabilities
Equity attributable to shareholders
Share capital 18 1,291,500 719,000
Share premium 18 4,403,094 3,460,595
Share based payments reserve 19 375,135 366,708
Merger relief reserve
1
20 3,700,000 450,000
Retained deficit (2,288,350) (981,620)
Total equity 7,481,379 4,014,683
Liabilities
Current liabilities
Trade and other payables 16 183,804 127,650
Total liabilities 183,804 127,650
Total equity and liabilities 7,665,183 4,142,333
1
In the prior period Merger relief reserve was not applied for the consideration shares issued for the acquisition of Lyramid, in error. £450,000 previously recorded as
share premium has been reclassified into a merger relief reserve in accordance with the UK Companies Act. There has been no impact to the prior period’s
consolidated statement of comprehensive income or net asset position.
The notes to the financial statements form an integral part of these financial statements.
The financial statements were approved by the Board and authorised for issue on 4 June 2023 and signed on its
behalf by:
Stephen West
Executive Chairman
Statement of Financial Position
Annual Report & Financial Statements 2022 49
Share
Ordinary Based Merger
Share Share Payment relief Retained Translation Total
capital Premium Reserve reserve earnings Reserve equity
£ £ £ £ £ £ £
On Incorporation – – – – 3,112 – 3,112
Loss for the period – – – – (917,433 ) – (917,433 )
Exchange differences – – – – – 624 624
Total comprehensive
income / (loss) for the period – – – – (914,321 ) 624 (913,697)
Transactions with owners
Ordinary Shares issued
(restated)
1
Share issue costs – (159,405 ) – – – – (159,405 )
Warrants charge – – 366,708 – – – 366,708
Total transactions with
owners (restated) 719,000 3,460,595 366,708 450,000 – – 4,996,303
As at 31 December 2021
(restated) 719,000 3,460,595 366,708 450,000 (914,321 ) 624 4,082,606
Loss for the period – – – – (1,615,417 ) – (1,615,417 )
Exchange differences – – – – – (14,989 ) (14,989 )
Total comprehensive
income / (loss) for the year – – – (1,615,417 ) (14,989 ) (1,630,406 )
Transactions with owners
Ordinary shares issued 572,500 942,499 – 3,250,000 – – 4,764,999
Stamp duty on share issue (18,990 ) (18,990 )
Warrants charge – – 8,427 – – – 8,427
Total transactions with
owners 572,500 942,499 8,427 3,250,000 (18,990 ) – 4,754,436
As at 31 December 2022 1,291,500 4,403,094 375,135 3,700,000 (2,548,728 ) (14,365 ) 7,206,636
1
In the prior period Merger relief reserve was not applied for the consideration shares issued for the acquisition of Lyramid, in error. £450,000 previously recorded as
share premium has been reclassified into a merger relief reserve in accordance with the UK Companies Act. There has been no impact to the prior period’s
consolidated statement of comprehensive income or net asset position.
The notes to the financial statements form an integral part of these financial statements.
Consolidated Statement of Changes in Equity
50 Roquefort Therapeutics plc
Share
Ordinary Merger Based
Share Share relief Payment Retained Total
capital Premium reserve Reserves earnings equity
£ £ £ £ £ £
On Incorporation – – – – –
Loss for the period – – – (981,620) (981,620)
Total comprehensive loss
for the period – – – (981,620) (981,620)
Transactions with owners
Ordinary Shares issued (restated)
1
719,000 3,620,000 450,000 – – 4,789,000
Share issue costs – (159,405) – – – (159,405)
Warrants issued – – – 366,708 – 366,708
Total transactions with
owners (restated) 719,000 3,460,595 450,000 366,708 – 4,996,303
As at 31 December 2021 (restated) 719,000 3,460,595 450,000 366,708 (981,620) 4,014,683
Loss for the year – – – – (1,287,740) (1,287,740)
Total loss for the year – – – – (1,287,740) (1,287,740)
Transactions with owners
Ordinary Shares issued 572,500 942,499 3,250,000 – – 4,764,999
Stamp duty on share issue (18,990) (18,990)
Warrants issued – – – 8,427 – 8,427
Total transactions with owners 572,500 942,499 3,250,000 8,427 (18,990) 4,754,436
As at 31 December 2022 1,291,500 4,403,094 3,700,000 375,135 (2,288,350) 7,481,379
1
In the prior period Merger relief reserve was not applied for the consideration shares issued for the acquisition of Lyramid, in error. £450,000 previously recorded as
share premium has been reclassified into a merger relief reserve in accordance with the UK Companies Act. There has been no impact to the prior period’s
consolidated statement of comprehensive income or net asset position.
The notes to the financial statements form an integral part of these financial statements.
Statement of Changes in Equity
Annual Report & Financial Statements 2022 51
Restated
Year ended Period ended
31 December 31 December
2022 2021
Note £ £
Cash flow from operating activities
Loss before income tax (1,634,303 ) (996,068 )
Adjustments for:
Amortisation – –
Foreign Exchange (9,918 ) 765
Non-cash adjustment – (2,602 )
Share based payment 19 8,427 366,708
Taxation 18,886 –
Changes in working capital:
Increase in trade and other receivables
2
(20,318 ) (24,434 )
Increase in trade and other payables 59,750 129,525
Decrease in Inventory – 9,273
Net cash used in operating activities (1,577,476 ) (516,833 )
Cash flow from Investing activities
Acquisition of subsidiary, net of cash acquired
1
(103,478 ) (606,226 )
Net Cash used in investing activities (103,478 ) (606,226 )
Cash flows from financing activities
Proceeds from the issue of ordinary shares
1 2
18 3,121,202 2,182,798
Share issue costs 18 (18,990 ) (159,405 )
Net cash from financing activities 3,102,212 2,023,393
Net increase in cash and cash equivalents 1,421,258 900,335
Cash and cash equivalents at the beginning of the period 899,721 –
Foreign exchange impact on cash 1,995 (614 )
Cash and cash equivalents at the end of the period 15 2,322,974 899,721
1
An error was identified in the prior year's cash flow statement. The error pertains to £500,000 of consideration shares issued for the acquisition of
Lyramid Pty Ltd, with no cashflow, that was incorrectly included in these line items. This was incorrectly considered as cash inflow from ‘Proceeds from the issue of
ordinary shares’ and cash outflow for ‘Acquisition of subsidiary, net of cash acquired’. There is no impact on the company and consolidated statement of
comprehensive income or statement of financial position.
2
An error was identified in the prior year's cash flow statement. The error pertains to £2,106,202 of proceeds from share issues which was recorded in 2021 but not
received until after period end. As a result, the Group has restated the cash flow from ‘Proceeds from the issue of ordinary shares’ and ‘Increase in trade and other
receivables’. The impact of the correction on the prior year's financial results is a decrease in the cash used in operating activities of £2,106,202 and a decrease in
cash from financing activities for the same amount. There is no impact on the consolidated and company statements of comprehensive income or statements of
financial position.
Consolidated Statement of Cash Flow
52 Roquefort Therapeutics plc
Unaudited
Year ended period ended
31 December 31 December
2022 2021
1
Note £ £
Cash flow from operating activities
Loss before income tax (1,287,740) (981,620)
Adjustments for:
Non-cash adjustment
Share based payment 19 8,427 366,708
Changes in working capital:
Increase in trade and other receivables (34,288) (30,222)
Increase in trade and other payables 56,153 127,649
Net cash used in operating activities (1,257,448) (517,485)
Cash flow from Investing activities
Acquisition of subsidiary (109,079) (648,496)
Borrowings to subsidiaries (318,822) –
Net Cash used in investing activities (427,901) (648,496)
Cash flows from financing activities
Proceeds from the issue of ordinary shares 18 3,121,202 2,183,000
Share issue costs 18 (18,990) (159,405)
Net Cash from financing activities 3,102,212 2,023,595
Net increase in cash and cash equivalents 1,416,863 857,614
Cash and cash equivalents at the beginning of the period 857,614 –
Foreign exchange impact on cash – –
Cash and cash equivalents at the end of the period 15 2,274,477 857,614
1
The Company Statement of Cashflow was incorrectly excluded from the 2021 Annual Report and as such the 2021 comparative amounts presented above have
not been audited.
The notes to the financial statements form an integral part of these financial statements.
Statement of Cash Flow
Annual Report & Financial Statements 2022 53
1. General Information
The address of its registered office is 85 Great Portland Street, First Floor, London W1W 7LT, United Kingdom .
The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to
treat cancers.
The Company listed on the London Stock Exchange (“LSE”) on 22 March 2021.
The consolidated financial statements of the Group have been prepared in accordance with UK adopted
International Accounting Standards as issued by the UK Accounting Standards Board (ASB). They have been
prepared under the assumption that the Group operates on a going concern basis.
2. New Standards and Interpretations
New and revised accounting standards adopted for the year ended 31 December 2022 did not have any material
impact on the Group’s accounting policies. There are a number of standards, amendments to standards, and
interpretations which have been issued by the IASB that are effective in future accounting periods that the Group
has decided not to adopt early. The following amendments are effective for the period beginning 1 January 2023:
• Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2);
• Definition of Accounting Estimates (Amendments to IAS 8); and
• Deferred Tax Related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12).
The following amendments are effective for the period beginning 1 January 2024:
• FRS 16 Leases (Amendment – Liability in a Sale and Leaseback);
• IAS 1 Presentation of Financial Statements (Amendment – Classification of Liabilities as Current or
Non-current); and
• IAS 1 Presentation of Financial Statements (Amendment – Non-current Liabilities with Covenants)
The Group is currently assessing the impact of these new accounting standards and amendments. The Group
does not believe that the amendments to IAS 1 will have a significant impact on the classification of its liabilities.
The Group does not expect any other standards issued by the IASB, but not yet effective, to have a material impact
on the Group.
3. Summary of Significant Accounting Policies
The principal accounting policies applied in the preparation of these financial statements are set out below. These
policies have been consistently applied to all the period presented, unless otherwise stated.
a) Basis of Preparation
The financial statements of Roquefort Therapeutics plc have been prepared in accordance with UK adopted
International Accounting Standards, and the Companies Act 2006.
The financial statements have been prepared on an accrual basis and under the historical cost convention.
b) Going Concern
The Directors have prepared financial forecasts to estimate the likely cash requirements of the Group over the
period to 30 June 2024, given its stage of development and lack of recurring revenues. In preparing these financial
forecasts, the Directors have made certain assumptions with regards to the timing and amount of future
expenditure over which they have control. The Directors have considered the sensitivity of the financial forecasts
to changes in key assumptions, including, among others, potential cost overruns within committed spend and
changes in exchange rates.
Notes to the Financial Statements
For the Year Ended 31 December 2022
54 Roquefort Therapeutics plc
The Group’s available resources are sufficient to cover the Group’s plans to complete pre-clinical development
activities and submit applications to commence clinical trials during 2023, however, they are not sufficient to
cover existing committed costs and the costs of planned activities for at least 12 months from the date of signing
these consolidated and company financial statements.
The Directors plan to raise further funds during 2023 (either through licencing deals and/or equity placements)
and have reasonable expectations that sufficient cash will be raised to fund the planned operations of the Group
for a period of at least 12 months from the date of approval of these financial statements. The funding requirement
indicates that a material uncertainty exists which may cast significant doubt over the Group’s and Company’s
ability to continue as a going concern, and therefore its ability to realise its assets and discharge its liabilities in
the normal course of business.
After due consideration of these forecasts, current cash resources, including the sensitivity of key inputs, and
plans to raise further funds, the Directors consider that the Group will have adequate financial resources to
continue in operational existence for the foreseeable future (being a period of at least 12 months from the date
of this report) and, for this reason, the financial statements have been prepared on a going concern basis. The
financial statements do not include the adjustments that would be required should the going concern basis of
preparation no longer be appropriate.
c) Basis of Consolidation
The Group’s financial statements consolidate those of the parent company and its subsidiaries as of 31 December
2022. Lyramid and Oncogeni have a reporting date at 31 December and 31 May respectively.
All transactions and balances between Group companies are eliminated on consolidation, including unrealised
gains and losses on transactions between Group companies. Where unrealised losses on intra-group asset sales
are reversed on consolidation, the underlying asset is also tested for impairment from a Group perspective.
Amounts reported in the financial statements of its subsidiary have been adjusted where necessary to ensure
consistency with the accounting policies adopted by the Group.
Profit or loss and other comprehensive income of subsidiaries acquired or disposed of during the year are
recognised from the effective date of acquisition, or up to the effective date of disposal, as applicable.
The Group attributes total comprehensive income or loss of subsidiaries between the owners of the parent and
the non-controlling interests based on their respective ownership interests.
d) Business combinations
The Group applies the acquisition method in accounting for business combinations. The consideration transferred
by the Group to obtain control of a subsidiary is calculated as the sum of the acquisition-date fair values of assets
transferred, liabilities incurred and the equity interests issued by the Group, which includes the fair value of any
asset or liability arising from a contingent consideration arrangement. Acquisition costs are expensed as incurred.
Assets acquired and liabilities assumed are generally measured at their acquisition-date fair values.
e) Foreign Currency Translation
i) Functional and Presentation Currency
The financial statements are presented in Pounds Sterling (GBP), which is the Group’s functional and presentation
currency.
ii) Transactions and Balances
Foreign currency monetary assets and liabilities are translated at the rates ruling at the reporting date. Exchange
differences arising on the retranslation of assets and liabilities are recognised immediately in profit or loss.
iii) Foreign operations
In the Group’s financial statements, all assets, liabilities and transactions of Group entities with a functional
currency other than GBP are translated into GBP upon consolidation. The functional currencies of entities within
the Group have remained unchanged during the reporting period.
Notes to the Financial Statements
continued
Annual Report & Financial Statements 2022 55
Notes to the Financial Statements
continued
On consolidation, assets and liabilities have been translated into GBP at the closing rate at the reporting date.
Goodwill and fair value adjustments arising on the acquisition of a foreign entity have been treated as assets and
liabilities of the foreign entity and translated into GBP at the closing rate on the acquisition date. Income and
expenses have been translated into GBP at the average rate of over the reporting period. Exchange differences
are charged or credited to other comprehensive income and recognised in the currency translation reserve in
equity. On disposal of a foreign operation, the related cumulative translation differences recognised in equity are
reclassified to profit or loss and are recognised as part of the gain or loss on disposal.
f) Segment Reporting
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-makers. The chief operating decision-makers, who are responsible for allocating resources and
assessing performance of the operating segments, has been identified as the executive Board of Directors.
All operations and information are reviewed together so that at present there is only one reportable operating
segment.
In the opinion of the Directors, during the period the Group operated in the single business segment of
biotechnology.
g) Goodwill and Intangible assets
Goodwill represents the future economic benefits arising from a business combination that are not individually
identified and separately recognised. Goodwill is carried at cost less accumulated impairment losses. Refer to
Note (h) for a description of impairment testing procedures.
Transactions where the definition of a business combination, per IFRS 3, is not met due to the asset or group of
assets not meeting the definition of a business, or where the concentration test affords the Directors the option
not to treat as a business, are recognised as an asset acquisition. The Group identifies and recognises the
individual identifiable assets acquired and liabilities assumed and allocates the cost of the group of assets and
liabilities (including directly attributable costs of making the acquisition) to the individual identifiable assets and
liabilities on the basis of their relative fair values at the date of purchase.
Other intangible assets, including licences and patents, that are acquired by the Group and have finite useful lives
are measured at cost less accumulated amortisation and any accumulated impairment losses. Refer to Note (h)
for amortisation procedures.
h) Impairment testing of goodwill, other intangible assets and property, plant and equipment
For impairment assessment purposes, assets are grouped at the lowest levels for which there are largely
independent cash inflows (cash-generating units). As a result, some assets are tested individually for impairment,
and some are tested at cash-generating unit level. Goodwill is allocated to those cash-generating units that are
expected to benefit from synergies of a related business combination and represent the lowest level within the
Group at which management monitors goodwill.
Cash-generating units to which goodwill has been allocated are tested for impairment at least annually. All other
individual assets or cash-generating units are tested for impairment whenever events or changes in
circumstances indicate that the carrying amount may not be recoverable.
An impairment loss is recognised for the amount by which the asset’s (or cash-generating unit’s) carrying amount
exceeds its recoverable amount, which is the higher of fair value less costs of disposal and value-in-use. To
determine the value-in-use, management estimates expected future cash flows from each cash-generating unit
and determines a suitable discount rate in order to calculate the present value of those cash flows. The data used
for impairment testing procedures are directly linked to the Group’s latest approved budget, adjusted as necessary
to exclude the effects of future reorganisations and asset enhancements. Discount factors are determined
individually for each cash-generating unit and reflect current market assessments of the time value of money
and asset-specific risk factors.
56 Roquefort Therapeutics plc
Impairment losses for cash-generating units reduce first the carrying amount of any goodwill allocated to that
cash-generating unit. Any remaining impairment loss is charged pro rata to the other assets in the
cash-generating unit.
Amortisation is calculated to write off the cost of intangible assets less their estimated residual values using the
straight‐line method over their estimated useful lives, from the date the assets are available for use and is
recognised in profit or loss. The available for use date is determined as the date from which a product is
commercialised – this had yet to occur, for all intangible assets, at 31 December 2022 and 2021. Goodwill is not
amortised.
i) Financial Instruments
IFRS 9 requires an entity to address the classification, measurement and recognition of financial assets and liabilities.
i) Classification
The Group classifies its financial assets in the following measurement categories:
• those to be measured at amortised cost.
The classification depends on the Group’s business model for managing the financial assets and the contractual
terms of the cash flows.
The Group classifies financial assets as at amortised cost only if both of the following criteria are met:
• the asset is held within a business model whose objective is to collect contractual cash flows; and
• the contractual terms give rise to cash flows that are solely payment of principal and interest.
ii) Recognition
Purchases and sales of financial assets are recognised on trade date (that is, the date on which the Group commits
to purchase or sell the asset). Financial assets are derecognised when the rights to receive cash flows from the
financial assets have expired or have been transferred and the Group has transferred substantially all the risks
and rewards of ownership.
iii) Measurement
At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset
not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of
the financial asset.
Transaction costs of financial assets carried at FVPL are expensed in profit or loss.
Receivables
Amortised cost: Assets that are held for collection of contractual cash flows, where those cash flows represent
solely payments of principal and interest, are measured at amortised cost. Interest income from these financial
assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition
is recognised directly in profit or loss and presented in other gains/(losses) together with foreign exchange gains
and losses. Impairment losses are presented as a separate line item in the statement of profit or loss.
iv) Impairment
The Group assesses, on a forward-looking basis, the expected credit losses associated with any debt instruments
carried at amortised cost. For trade receivables, the Group applies the simplified approach permitted by IFRS 9,
which requires expected lifetime losses to be recognised from initial recognition of the receivables.
j) Taxation
Taxation comprises current and deferred tax.
Current tax is based on taxable profit or loss for the period. Taxable profit or loss differs from profit or loss as
reported in the income statement because it excludes items of income and expense that are taxable or deductible
Notes to the Financial Statements
continued
Annual Report & Financial Statements 2022 57
in other years and it further excludes items that are never taxable or deductible. The asset or liability for current
tax is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.
Deferred tax is recognised on differences between the carrying amounts of assets and liabilities in the financial
information and the corresponding tax bases used in the computation of taxable profit and is accounted for using
the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary
differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be
available against which deductible temporary differences can be utilised. Such assets and liabilities are not
recognised if the temporary difference arises from initial recognition of goodwill or from the initial recognition
(other than in a business combination) of other assets and liabilities in a transaction that affects neither the
taxable profit nor the accounting profit.
Deferred tax liabilities are recognised for taxable temporary differences arising on investments in subsidiaries
and associates, and interests in joint ventures, except where the Group is able to control the reversal of the
temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future.
The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that
it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be
recovered.
Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled, or
the asset realised. Deferred tax is charged or credited to profit or loss, except when it relates to items charged or
credited directly to equity, in which case the deferred tax is also dealt with in equity.
Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets
against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the
Group intends to settle its current tax assets and liabilities on a net basis.
R&D tax rebate receivable represents refundable tax offsets, in cash, from the Australian Taxation Office (“ATO”)
in relation to expenditure incurred in the current year for eligible research and development activities. Research
and development activities are refundable at a rate of 43.5% for each dollar spent, subject to meeting certain
eligibility criteria. Funds are expected to be received subsequent to the lodgement of the income tax return and
research and development tax incentive schedule for the current financial year. The Group recognises a taxation
credit, in the year the cash is received, which generally relates to expenses during the prior period. In future periods
(which will include UK R&D tax credits), once an established pattern of successful claims is recorded, the Group
will consider an accruals basis, recording the tax credit and a receivable in the period the eligible expenditure was
incurred.
k) Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and in hand and demand deposits with banks and other financial
institutions, that are readily convertible into known amounts of cash, and which are subject to an insignificant risk
of changes in value.
l) Equity, reserves and dividend payments
Share capital represents the nominal (par) value of shares that have been issued.
Share premium includes any premiums received on issue of share capital. Any transaction costs directly associated
with the issuing of shares are deducted from share premium, net of any related income tax benefits.
Share based payments represents the value of equity settled share-based payments provided to employees, including
key management personnel, and third parties for services provided.
Translation reserve comprises foreign currency translation differences arising from the translation of financial
statements of the Group’s foreign entities into GBP on consolidation.
Retained losses represent the cumulative retained losses of the Group at the reporting date.
All transactions with owners of the parent are recorded separately within equity.
No dividends are proposed for the period.
Notes to the Financial Statements
continued
58 Roquefort Therapeutics plc
m) Earnings per Ordinary Share
The Company presents basic and diluted earnings per share data for its Ordinary Shares.
Basic earnings per Ordinary Share is calculated by dividing the profit or loss attributable to Shareholders by the
weighted average number of Ordinary Shares outstanding during the period.
Diluted earnings per Ordinary Share is calculated by adjusting the earnings and number of Ordinary Shares for
the effects of dilutive potential Ordinary Shares.
n) Employee benefits
Provision is made for Lyramid’s liability for employee benefits arising from services rendered by employees up to
the end of the reporting period. In determining the liability, consideration is given to employee wage increases
and the probability that the employee may satisfy vesting requirements.
Short term obligations
Liability for wages and salaries, including non-monetary benefits, annual leave, long service leave and
accumulating sick leave expected to be settled within 12 months of the reporting date are recognised in other
payables in respect of employees’ services up to the reporting date and are measured at the amounts expected
to be paid when the liabilities are settled.
Other long-term employee benefit obligations
Liability for annual leave and long service leave not expected to be settled within 12 months from the reporting
date is recognised in the provision for employee benefits and measured as the present value of expected future
payments to be made in respect of services provided by employees up to the reporting date, using the projected
unit credit method. Consideration is given to expected future wage and salary levels, of employee departures and
period of service.
Retirement benefit obligations
Contributions for retirement benefit obligations are recognised as an expense as they become payable. Prepaid
contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payment is
available. Contributions are paid into the fund nominated by the employee.
Employee benefits provision
The liability for employee benefits expected to be settled more than 12 months from the reporting date are
recognised and measured at the present value of the estimated future cash flows to be made in respect of all
employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and
pay increases through promotion and inflation have been taken into account.
o) Leases
Leases are accounted for by recognising a right-of-use asset and a lease liability, except for leases of low value
assets and leases with a duration of 12 months or less, for which the lease cost is expensed in the period to which
it relates.
A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at
the present value of the lease payments to be made over the term of the lease, discounted using the interest rate
implicit in the lease or, if that rate cannot be readily determined, the consolidated entity’s incremental
borrowing rate.
Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that
depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a
purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination
penalties.
The variable lease payments that do not depend on an index or a rate are expensed in the period in which they
are incurred. Lease liabilities are measured at amortised cost using the effective interest method. The carrying
amounts are remeasured if there is a change in the following: future lease payments arising from a change in an
index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties.
Notes to the Financial Statements
continued
Annual Report & Financial Statements 2022 59
When a lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit
or loss if the carrying amount of the right-of-use asset is fully written down.
Right-of-use assets are initially measured at the amount of the lease liability, reduced for any lease incentives
received, and increased for: lease payments made at or before commencement of the lease; initial direct costs
incurred; and the amount of any provision recognised where the Group is contractually required to dismantle,
remove or restore the leased asset.
For contracts that both convey a right to the Group to use an identified asset and require services to be provided
to the Group by the lessor, the Group has elected to account for the entire contract as a lease, i.e. it does not
allocate any amount of the contractual payments to, and account separately for, any services provided by the
supplier as part of the contract.
p) Share-based payments
The Company has applied the requirements of IFRS 2 Share-based payments.
The Company issues equity settled share-based payments to the Directors and to third parties for the provision
of services provided for assistance in raising private equity. Equity settled share-based payments are measured
at fair value at the date of grant, or the date of the service provided. The fair value determined at the grant date or
service date of the equity settled share-based payment is recognised as an expense, or recognised against share
premium where the service received relates to assistance in raising equity, with a corresponding credit to the
share based payment reserve. The fair value determined at the grant date of equity settled share based payment
is expensed on a straight-line basis over the life of the vesting period, based on the Company’s estimate of shares
that will eventually vest. Once an option or warrant vests, no further adjustment is made to the aggregate
expensed.
The fair value Is measured by use of the Black Scholes model as the Directors view this as providing the most
reliable measure of valuation. The expected life used in the model has been adjusted, based on management’s
best estimates, for the effects of non-transferability, exercise restrictions and behavioural considerations. The
market price used in the model is the quoted LSE closing price. The fair value calculated is inherently subjective
and uncertain due to the assumptions made and the limitation of the calculation used.
q) Financial Risk Management Objectives and Policies
The Group does not enter into any forward exchange rate contracts.
The main financial risks arising from the Group’s activities are market risk, interest rate risk, foreign exchange
risk, credit risk, liquidity risk and capital risk management. Further details on the risk disclosures can be found in
Note 21.
r) Significant accounting judgements, estimates and assumptions
The preparation of the financial statements in conformity with International Financial Reporting Standards requires
the use of certain critical accounting estimates. It also requires management to exercise its judgement in the
process of applying the Group’s accounting policies.
Estimates and judgements are continually evaluated, and are based on historical experience and other factors,
including expectations of future events that are believed to be reasonable under the circumstances. The Directors
consider the significant accounting judgements, estimates and assumptions used within the financial statements
to be:
Impairment of non-financial assets and goodwill
In assessing impairment, management estimates the recoverable amount of each asset or cash-generating unit
based on estimated cashflows from similar market transactions.
Notes to the Financial Statements
continued
60 Roquefort Therapeutics plc
Business combinations
Management uses valuation techniques when determining the fair values of certain assets and liabilities acquired
in a business combination (see Notes 1d and 4.2). In particular, the fair value of contingent consideration is
dependent on the market capitalisation of the Group exceeding a threshold amount.
Management has performed the optional concentration test available under IFRS3, in order to determine that the
acquisition of Oncogeni Ltd can be treated as an asset acquisition. Judgement is required to determine whether
‘substantially all’ the fair value is concentrated in a single asset or group of assets, and when considering a group
of assets, assessing whether those assets are similar. In determining whether assets are similar, judgement is
required to consider the nature of each single identifiable asset and the risks associated with managing and
creating outputs from the assets (that is, the risk characteristics). Management has considered that the two
separate in-progress research and development programs, MK cell therapy and STAT-6 siRNA therapeutics, are
similar as they are both pre-clinical stage oncology treatments.
Share Based Payments
In the year to 31 December 2022, 900,000 (31 December 2021: 35,875,000) warrants were granted. When
accounting for the share-based payment expense in respect of those warrants granted, management must
calculate the fair value of the share warrants issued. Management have done so using the Black Scholes model,
however, a number of the inputs in this model are subjective and thus management must make estimates.
4. Acquisitions
4.1. Acquisition of Oncogeni Limited
On 16 September 2022, the Group acquired 100% of the equity instruments of Oncogeni Limited, a UK based
business, thereby obtaining control. The acquisition was assessed as being complementary to the Group’s existing
pre-clinical drug development business. The Group applied the concentration test under IFRS3 and considered it
as an asset acquisition.
The details of the asset acquisition are as follows:
| Fair value of consideration transferred | £ |
| Equity consideration | 3,750,000 |
| Costs directly attributable to acquisition | 109,079 |
| Total | 3,859,079 |
| Recognised amounts of identifiable net assets at book values | |
| Trade and other receivables | 7,294 |
| Cash and cash equivalents | 5,601 |
| Total current assets | 12,895 |
| Trade and other payables | 15,792 |
| Total current liabilities | 15,792 |
| Identifiable net liabilities | 2,897 |
| Intangible asset at cost | 3,861,975 |
| Consideration transferred settled in cash | – |
| Cash and cash equivalents acquired | 5,601 |
| Net cash inflow on acquisition | 5,601 |
Consideration transferred
The acquisition of Oncogeni was settled for a consideration of £3,750,000, all of which was payable in shares.
£109,079 of costs directly attributable to the acquisition have been included in the consideration of the transaction.
Notes to the Financial Statements
continued
Annual Report & Financial Statements 2022 61
Identifiable net assets
The carrying value of the trade and other receivables acquired as part of the business combination amounted to
£7,294. As of the acquisition date, the Group’s best estimate of the contractual cash flow not expected to be
collected amounted to zero.
4.2. Acquisition of Lyramid Pty Limited
On 21 December 2021, Roquefort Therapeutics acquired 100% of the equity instruments of Lyramid Pty Limited,
an Australian based business, thereby obtaining control. The acquisition was made in line with the Group’s stated
strategic objective to pursue investments in the global biotechnology sector.
The details of the business combination as follows:
| Fair value of consideration transferred | £ |
| Amount settled in cash | 648,495 |
| Equity consideration | 500,000 |
| Loans assigned at acquisition | (132,800) |
| Fair value of contingent consideration | – |
| Total | 1,015,695 |
| Recognised amounts of identifiable net assets at book values | |
| Inventories | 9,273 |
| Trade and other receivables | 42,674 |
| Cash and cash equivalents | 42,270 |
| Total current assets | 94,217 |
| Borrowings | 212,065 |
| Deferred tax liabilities | 281,911 |
| Total non-current liabilities | 493,976 |
| Other liabilities | 28,195 |
| Trade and other payables | 37,881 |
| Total current liabilities | 66,076 |
| Identifiable net liabilities | 465,835 |
| Intangible asset at fair value | 1,481,530 |
| Consideration transferred settled in cash | 648,496 |
| Cash and cash equivalents acquired | (42,270) |
| Net cash outflow on acquisition | 606,226 |
| Acquisition costs charged to expenses | 224,744 |
Consideration transferred
The acquisition of Lyramid was settled for a consideration of £1,148,495; £648,495 being payable in cash and
£500,000 payable in shares. On acquisition, loans of £132,800 were assigned from the previous owner to the
Company.
The purchase agreement included an additional contingent deferred consideration to the Seller to be satisfied in
the form of Ordinary Shares as follows:
(a) if prior to fi fth anniversary of Admission (on 21 December 2021), the Company’s market capitalisation
exceeds £25,000,000 for a period of 5 or more consecutive trading days the Company shall issue to the
Seller (or its nominee) 5,000,000 Ordinary Shares; and
(b) if prior to fifth anniversary of Admission (on 21 December 2021) the Company’s market capitalisation
exceeds £50,000,000 for a period of 5 or more consecutive trading days the Company shall issue to the
Seller (or its nominee) a further 5,000,000 Ordinary Shares.
Notes to the Financial Statements
continued
62 Roquefort Therapeutics plc
Notes to the Financial Statements
continued
The fair value of contingent deferred consideration was estimated to be nil at acquisition, at 31 December 2021
and at 31 December 2022.
Acquisition-related costs amounting to £224,744 are not included as part of consideration transferred and have
been recognised as an expense in the consolidated statement of profit or loss, as part of other expenses.
Identifiable net assets
The fair value of the trade and other receivables acquired as part of the business combination amounted to
£42,674. As of the acquisition date, the Group’s best estimate of the contractual cash flow not expected to be
collected amounted to zero.
Lyramid’s contribution to the Group results
Lyramid incurred a loss of £14,449, for the eleven days from 21 December 2021 to the reporting date. Revenue
for this period was £719.
If Lyramid had been acquired on 17 August 2020, revenue of the Group for the period would have been £23,857,
and loss for the period would have increased by £193,881.
5. Investments in subsidiaries
The parent company has investments in the following subsidiary undertakings which are unlisted:
| Country of | Proportion of | |||
| Name | incorporation | Holding | voting rights | Principal activity |
| Subsidiary undertakings | ||||
| Oncogeni Limited | England | Ordinary shares | 100% | Biotechnology research company |
| Lyramid Pty Limited | Australia | Ordinary shares | 100% | Biotechnology research company |
| Tumorkine Pty Limited | Australia | Ordinary shares | 100% | Dormant |
6. Directors’ and Employees’ Remuneration
Directors’ Remuneration
| Year ended | Period ended | |
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Fees to directors | 308,692 | 47,301 |
| Bonus | – | 10,000 |
| Post-employment benefits | 12,162 | – |
| Share based payment charge | 5,616 | 178,053 |
| 326,470 | 235,354 |
The total remuneration of the highest paid director was £118,305 (2021: £160,825), including pension
contributions of £4,054 (2021: £Nil).
Further information about the remuneration of individual directors are provided in the Directors’ Remuneration
Report.
Annual Report & Financial Statements 2022 63
Notes to the Financial Statements
continued
Remuneration of Key Management Personnel
| Restated | ||
| Year ended | Period ended | |
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Salaries and short-term employee benefits | 308,692 | 49,200 |
| Long term benefits | – | 10,221 |
| Post-employment benefits | 12,162 | 186 |
| Share based payment charge | 5,616 | 240,517 |
| 326,470 | 300,124 |
2021 Remuneration of key management personnel has been restated to include all directors and Graham
Robertson; it was previously disclosed incorrectly as Graham Robertson only, which does not meet the IAS24
definition of key management personnel as requiring the inclusion of directors. Total key management personnel
remuneration was therefore restated from £64,770 to £300,124.
For 2022, upon the appointment of Ajan Reginald as director and Chief Executive Officer, key management
personnel has been re-defined as the directors of Roquefort Therapeutics plc only.
Average number of employees during the year (including Directors full time equivalent)
| Year ended | Period ended | |
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Continuing operations | 5 | 1 |
At 31 December 2022 the Company had nine (9) employees in total; seven (7) Directors: Stephen West, Ajan
Reginald, Martin Evans, Michael Stein, Simon Sinclair, Darrin Disley, Jean Duvall and two (2) laboratory staff:
Sabena Sultan and Emma Morris.
Lyramid’s sole employee is Graham Robertson.
Oncogeni has no employees.
7. Revenue
Revenue in the period was £NIL (2021: £716).
8. Other comprehensive income
Items credited/(charged) to the other comprehensive income line of the statement of comprehensive income
relate to the impact of foreign exchange movements on cash and cash equivalents balances. The corresponding
movement is offset against the foreign exchange reserve in the statement of financial position:
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Opening Balance | 624 | – |
| Foreign exchange impact | (14,989) | 624 |
| Closing Balance | (14,365) | 624 |
64 Roquefort Therapeutics plc
Notes to the Financial Statements
continued
9. Operating Loss
The following items have been charged/(credited) to the statement of comprehensive income in arriving at the
Group’s operating loss from continuing operations:
| Year ended | Period ended | |
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Directors’ and employee costs | 365,564 | 59,607 |
| Legal fees | 46,373 | 31,165 |
| Consulting and professional fees | 209,768 | 125,807 |
| Other expenditure | 684,854 | 35,818 |
| Administrative expenses | 1,306,561 | 252,392 |
| Costs associated with the IPO | – | 182,053 |
| Share based payments to directors and senior management | 8,427 | 248,326 |
| Costs associated with acquisition of subsidiary | – | 224,744 |
| Research and development expenditure | ||
| 1 | ||
| 319,315 | 698 | |
| Total operating expenditure | 1,634,303 | 908,213 |
1
Includes short term lease expense of £81,250 for rental of laboratory during the year (2021: £Nil).
During the year the Group obtained the following services from its auditor:
| Year ended | Period ended | |
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Audit Services | ||
| Statutory audit – Group and Company | 157,336 | 22,000 |
The Group incurred no finance costs during the year ended 31 December 2022 (2021: £nil).
10. Taxation
| Year ended | Period ended | |
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Current tax | – | – |
| Deferred tax | – | – |
| Australian R&D rebate | ||
| 1 | ||
| 18,886 | – | |
| Income tax credit | 18,886 | – |
1
R&D tax rebate receivable represents refundable tax offsets, in cash, from the Australian Taxation Office (“ATO”) in relation to expenditure incurred in the prior year
for eligible research and development activities
Annual Report & Financial Statements 2022 65
Notes to the Financial Statements
continued
Income tax can be reconciled to the loss in the statement of comprehensive income as follows:
| Restated | ||
| Year ended | Period ended | |
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Loss | (1,615,417) | (917,433) |
| R&D tax rebate | 18,886 | – |
| (1,634,303) | (917,433) | |
| Tax at the UK Corporation rate of 19% | 310,517 | 174,312 |
| Effect of overseas tax rates | 21,642 | – |
| Expenditure disallowable for taxation | (82,705) | (75,850) |
| Share based payment temporary difference on which | ||
| no deferred tax asset has been recognised | (1,067) | (47,181) |
| Remeasurement of deferred tax for changes in tax rates | 74,363 | 12,377 |
| Tax losses on which no deferred tax asset has been recognised | (322,750) | (63,658) |
| Total tax (charge)/credit | – | – |
| UK | – | – |
| Overseas | – | – |
| Total tax (charge)/credit) | – | – |
The above tax reconciliation and unrecognised deferred tax disclosure in the 2021 Annual Report was incorrectly
calculated based on the 2021 financial year tax rate of 19% applied to the consolidated accounting loss of
£917,433, rather than the substantively enacted expected future tax rate when the differences reverse, applied to
the taxable loss, and incorrectly disclosed all such deferred tax (£175,000) as relating to losses. The 2021 deferred
tax disclosures have been restated to reflect the expenditure disallowable for taxation to derive the taxable losses
and share-based payment timing differences, the substantively enacted expected future tax rate when the
differences reverse of 25%, and to disclose tax losses separately from other timing differences such as share-
based payments, and deferred tax thereon. Disclosures have been expanded to separate UK from Australian tax
losses and deferred tax thereon.
The Group has accumulated tax losses of approximately £1,557,117 (Restated 2021: £254,638) that are available,
under current legislation, to be carried forward indefinitely against future profits.
An error was identified in the prior year's accumulated tax losses and the amount has been restated.
The tax losses can be broken down to the following:
| Restated | ||
| Year ended | Period ended | |
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| AU | (125,138) | (62,784) |
| UK | (1,431,979) | (191,854) |
| Carried forward tax losses | (1,557,117) | (254,638) |
66 Roquefort Therapeutics plc
Notes to the Financial Statements
continued
A deferred tax asset has not been recognised in respect of these losses due to the uncertainty of future profits.
The amount of the deferred tax asset not recognised is approximately £389,279 (2021: £63,660). An error was
identified in the prior year's deferred tax asset amount and the amount has been restated.
| Restated | ||||
| Year ended | Period ended | |||
| 31 December 2022 | 31 December 2021 | |||
| £ | £ | |||
| UK | AU | UK | AU | |
| Tax effect of temporary differences: | ||||
| Accumulated losses | (357,995) | (31,285) (47,964) | (15,696) | |
| Deductible temporary differences | (14,181) | – | (53,502) | – |
| Deferred tax (asset)/liability not recognised | (372,176) | (31,285) | (101,466) | (15,696) |
On 3 March 2021, the Chancellor announced that the corporation tax rate would be increasing to 25% from 1 April
2023 for Companies with profits over £250,000. The Company calculated the UK deferred tax balances at 25%
and the Australian deferred tax balances at the current small company tax rate of 25%, which is expected to
continue in future periods.
11. Earnings per share
| Year ended | Period ended | |
| 31 December | 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Loss attributable to equity shareholders | (1,615,417) | (917,433) |
| Weighted average number of ordinary shares | 103,479,476 | 24,701,793 |
| Loss per share in pence | ||
| Basic | (1.56) | (3.71) |
| Diluted | (1.56) | (3.71) |
There is no difference between the basic and diluted earnings per share as the effect would be to decrease
earnings per share.
As at the end of the financial period there were 35,272,000 (2021: 34,375,000) warrants in issue, which could
potentially have an anti-dilutive impact depending on the results of the Company.
12. Intangible Assets
| In-progress R&D | Goodwill | Total | |
| £ | £ | £ | |
| Cost | |||
| At 1 January 2022 | 1,199,619 | 281,911 | 1,481,530 |
| Acquired through asset acquisition | 3,861,975 | – | 3,861,975 |
| At 31 December 2022 | 5,061,594 | 281,911 | 5,343,505 |
| Amortisation | |||
| At 1 January 2022 | – | – | |
| Amortisation | – | – | – |
| Impairment Charge | – | – | – |
| At 31 December 2022 | – | – | – |
| Carrying value | |||
| At 31 December 2022 | 5,061,594 | 281,911 | 5,343,505 |
The Directors have concluded that there has been no impairment of the goodwill associated with the acquisition
of Lyramid Pty Limited at 31 December 2022. The Goodwill represents the offsetting balance to the deferred tax
liability for the acquisition of Lyramid.
Annual Report & Financial Statements 2022 67
Notes to the Financial Statements
continued
| In-progress R&D | Goodwill | Total | |
| £ | £ | £ | |
| Cost | |||
| At 17 August 2020 | – | – | – |
| Acquisition through business combination | 1,119,619 | 281,911 | 1,481,530 |
| At 31 December 2021 | 1,119,619 | 281,911 | 1,481,530 |
| Amortisation | |||
| At 17 August 2020 | – | – | – |
| Impairment Charge | – | – | – |
| At 31 December 2021 | – | – | – |
| Carrying value | |||
| At 17 August 2020 | – | ||
| At 31 December 2021 | 1,119,619 | 281,911 | 1,481,530 |
At 31 December 2022, the Group performed its annual impairment test in relation to intangible assets not yet available
for use and identified no indicators of impairment in line with IAS 36 Impairment of Assets, as all acquired in-progress
R&D programs are in active development and progressing as planned. At the test date, it was determined that due to the
ongoing pre-clinical research and development using in-progress R&D acquired, there was too much uncertainty to
estimate a value-in-use, based on discounted future cash flows from the assets. The Group estimated fair value less
costs to sell, by referring to market transactions for pre-clinical and clinical oncology drug candidates. Due to the nature
of oncology drug development, the fair value is not considered to be particularly sensitive to any one underlying valuation
assumption other than the ultimate outcome of drug development and commercialisation, which is binary.
Accordingly, the Group has concluded that the estimated recoverable amount of the assets did exceed the carrying
amount and therefore no impairment was identified.
68 Roquefort Therapeutics plc
Notes to the Financial Statements
continued
13. Investments
| Shares in | |||
| Investment | Investment in | subsidiary | |
| in Lyramid Ltd | Oncogeni Ltd | undertakings | |
| Company | £ | £ | £ |
| Cost at 1 January 2022 | 1,015,695 | – | 1,015,695 |
| Additions | – | 3,859,079 | 3,859,079 |
| Cost at 31 December 2022 | 1,015,695 | 3,859,079 | 4,874,774 |
| Impairment | |||
| At 1 January 2022 | – | – | – |
| Charge for the period | – | – | – |
| At 31 December 2022 | – | – | – |
| Net book value at 31 December 2022 | 1,015,695 | 3,859,079 | 4,874,774 |
| Investment in | |
| Lyramid Ltd | |
| Company | £ |
| Cost at 17 August 2020 | – |
| Additions | 1,015,695 |
| Cost at 31 December 2021 | 1,015,695 |
| Impairment | |
| At 17 August 2020 | – |
| Charge for the period | – |
| At 31 December 2021 | – |
| Net book value at 17 August 2020 | – |
| Net book value at 31 December 2021 | 1,015,695 |
In the period the Company acquired 100% of the issued shares of Oncogeni Limited. The Directors have concluded
that there has been no impairment to the investment in Oncogeni Limited at 31 December 2022.
In 2021 the Company acquired 100% of the issued shares of Lyramid Pty Limited. The Directors have concluded
that there has been no impairment to the investment in Lyramid Pty Limited at 31 December 2022 or
31 December 2021.
Impairment review disclosures required by IAS36 are included in note 12 to the financial statements.
14. Trade and other receivables
| Group | Group | Company | Company | |
| 31 December | 31 December | 31 December | 31 December | |
| 2022 | 2021 | 2022 | 2021 | |
| £ | £ | £ | £ | |
| Trade receivables | – | 17,825 | – | – |
| Other receivables | 45,124 | 2,135,031 | – | 2,130,875 |
| Prepayments and accrued income | 56,614 | 25,927 | 64,309 | 5,349 |
| 101,738 | 2,178,783 | 64,309 | 2,136,224 |
There are no material differences between the fair value of trade and other receivables and their carrying value at
the year end.
The other receivables balance in the prior year relates primarily to shares issued in December 2021 as part of the
acquisition of Lyramid. These monies were collected in full in January 2022.
No receivables were past due or impaired at the year end.
Annual Report & Financial Statements 2022 69
Notes to the Financial Statements
continued
15. Cash and cash equivalents
| Group | Group | Company | Company | |
| 31 December | 31 December | 31 December | 31 December | |
| 2022 | 2021 | 2022 | 2021 | |
| £ | £ | £ | £ | |
| Cash at bank and in hand | 2,322,974 | 899,721 | 2,274,478 | 857,614 |
The Directors consider the carrying amount of cash and cash equivalents approximates to their fair value.
16. Trade and other payables
| Group | Group | Company | Company | |
| 31 December | 31 December | 31 December | 31 December | |
| 2022 | 2021 | 2022 | 2021 | |
| £ | £ | £ | £ | |
| Trade creditors | 68,379 | 40,718 | 26,209 | 962 |
| Accruals and other creditors | 211,291 | 154,799 | 157,593 | 126,688 |
| 279,670 | 195,517 | 183,802 | 127,650 |
The fair value of trade and other payables approximates their current book values.
17. Deferred tax assets and liabilities
| Group | Company | |
| £ | £ | |
| At 1 January 2022 | 281,911 | – |
| Released in year | – | – |
| Deferred tax liability recognised in business combination | – | – |
| At 31 December 2022 | 281,911 | – |
| At 17 August 2020 | – | – |
| Deferred tax liability recognised in business combination | 281,911 | – |
| At 31 December 2021 | 281,911 | – |
See note 4.2 – Acquisition of Lyramid Pty Limited.
70 Roquefort Therapeutics plc
18. Share capital
| Ordinary | Share | Share | ||
| Shares | Capital | Premium | Total | |
| Group and Company | No. | £ | £ | £ |
| 1 | ||||
| Issue of ordinary shares on incorporation | ||||
| 5,000,000 | 50,000 | – | 50,000 | |
| 2 | ||||
| Issue of ordinary shares | ||||
| 7,400,000 | 74,000 | – | 74,000 | |
| 3 | ||||
| Issue of ordinary shares | ||||
| 20,000,000 | 200,000 | 800,000 | 1,000,000 | |
| 4 | ||||
| Exercise of broker warrants | ||||
| 1,500,000 | 15,000 | – | 15,000 | |
| 5 | ||||
| Issue of ordinary shares | ||||
| 3,000,000 | 30,000 | 120,000 | 150,000 | |
| 6 | ||||
| Issue of ordinary shares | ||||
| 30,000,000 | 300,000 | 2,700,000 | 3,000,000 | |
| 7 | ||||
| Issue of ordinary shares | ||||
| 5,000,000 | 50,000 | – | 50,000 | |
| Share issue costs | – | – | (159,405) | (159,405) |
| At 31 December 2021 (restated) | 71,900,000 | 719,000 | 3,460,595 | 4,179,595 |
| 8 | ||||
| Issue of ordinary shares | ||||
| 50,000,000 | 500,000 | – | 500,000 | |
| 9 | ||||
| Issue of ordinary shares | ||||
| 7,249,998 | 72,500 | 942,499 | 1,014,999 | |
| At 31 December 2022 | 129,149,998 | 1,291,500 | 4,403,094 | 5,694,594 |
The share premium account balance for the year ended 31 December 2021 has been restated due to an amount
of £450,000 previously recognised in 2021 as being credited to the share premium account, reclassified as being
credited to the merger reserve (refer to the consolidated and company statements of financial position, and to
Note 20).
1
On incorporation on 17 August 2020, the Company issued 5,000,000 ordinary shares of £0.01 at their nominal value of £0.01 per share.
2
On 20 November 2020, the Company issued 7,400,000 ordinary shares at their nominal value of £0.01 per share.
3
On admission to the Standard List of the LSE on 22 March 2021, 20,000,000 shares were issued at a placing price of £0.05 per share.
4
On 19 April 2021 1,500,000 brokers warrants were exercised at the exercise price of £0.01 per share, resulting in the issue of 1,500,000 ordinary shares.
5
On 18 August 2021, the Company issued 3,000,000 ordinary shares of £0.01 at an issue price of £0.05 per share.
6
On 21 December 2021, the Company issued 30,000,000 ordinary shares of £0.01 at an issue price of £0.10 per share.
7
On 21 December 2021, the Company issued 5,000,000 ordinary shares of £0.01 at an issue price of £0.10 per share.
8
On 16 September 2022, the Company issued 50,000,000 ordinary shares of £0.01 to acquire Oncogeni Limited, recorded at the market price of £0.075 per share.
9
On 16 September 2022, the Company issued 7,249,998 ordinary shares of £0.01 for cash at a placing price of £0.14 per share.
19. Share Based Payment Reserves
| 2022 | 2021 | |
| Group and Company | £ | £ |
| Opening balance | 366,708 | – |
| Directors warrants issued | ||
| 1 | ||
| – | 6,833 | |
| Broker seed warrants issued | ||
| 2 | ||
| – | 60,002 | |
| Broker placing warrants issued | ||
| 3 | ||
| – | 8,076 | |
| Completion warrants issued | ||
| 4 | ||
| – | 100,947 | |
| Senior management warrants issued | ||
| 5 | ||
| – | 140,544 | |
| Optiva warrants issued | ||
| 6 | ||
| – | 44,417 | |
| Orana warrants issued | ||
| 7 | ||
| – | 5,889 | |
| NED and Advisor warrants issued | ||
| 8 | ||
| 8,427 | – | |
| At 31 December | 375,135 | 366,708 |
1
On admission to LSE on 22 March 2021 750,000 directors’ warrants were issued that entitle the warrant holder to subscribe for one Ordinary Share at £0.05 per ordinary share
and a further 750,000 directors warrants were issued that entitle the warrant holder to subscribe for one ordinary share at £0.10 per ordinary share. Upon issue all warrants
vested on the earlier of 12 months or the Company completing the acquisition of a company or business. All warrants vested on 21 December 2021 when the Company completed
the acquisition of Lyramid Pty Ltd.
2
On admission to LSE on 22 March 2021 1,500,000 brokers warrants were issued that entitle the warrant holder to subscribe for one Ordinary Share at £0.01 per ordinary share.
The warrants vested immediately upon grant.
3
On admission to LSE on 22 March 2021, 480,000 Broker Placing Warrants were issued that entitle the warrant holder to subscribe for one ordinary share at the placing price of
£0.05 per ordinary share. The warrants vested immediately upon grant.
4
On readmission to LSE on 21 December 2021, 3,000,000 Completion Warrants were issued that entitle, Stephen West (the warrant holder) to subscribe for one ordinary share at
£0.10 per ordinary share. The warrants vested immediately upon grant.
5
On readmission to LSE on 21 December 2021, 4,500,000 Senior Management Warrants were issued that entitle the warrant holder to subscribe for one ordinary share at £0.15
per ordinary share. One third of the warrants vest on 21 December 2022, 21 December 2023 and 21 December 2024.
6
On readmission to LSE on 21 December 2021, 1,320,000 Optiva Warrants were issued that entitle the warrant holder to subscribe for one ordinary share at £0.10 per ordinary
share. The warrants vested immediately upon grant.
7
On re-admission to LSE on 21 December 2021, 175,000 Orana Warrants were issued that entitle the warrant holder to subscribe for one ordinary share at £0.10 per ordinary
share. The warrants vested immediately upon grant.
8
On 26 June 2022, Ms Jean Duvall, Dr Simon Sinclair and Professor Trevor Jones were awarded 300,000 NED and Advisor warrants each. These warrants entitle the warrant holder
to subscribe for one ordinary share at £0.15 per ordinary share. 50% Warrants are exercisable one year after grant date with the remaining balance exercisable two years after grant
date.
Notes to the Financial Statements
continued
Annual Report & Financial Statements 2022 71
The fair value of the services received in return for the warrants granted are measured by reference to the fair value of
the warrants granted. The estimate of the fair value of the warrants granted is measured based on the Black-Scholes
valuations model. Measurement inputs and assumptions are as follows:
| Number of | Share | Exercise | Expected | Expected | Risk free | Expected | |
| Warrant | warrants | Price | Price | volatility | life | rate* | dividends |
| Director | 750,000 | £0.05 | £0.05 | 50.00% | 5 | 0.15% | 0.00% |
| Director | 750,000 | £0.05 | £0.10 | 50.00% | 5 | 0.15% | 0.00% |
| Broker | 1,500,000 | £0.05 | £0.01 | 50.00% | 0.08 | 0.15% | 0.00% |
| Broker Placing | 480,000 | £0.05 | £0.05 | 50.00% | 3 | 0.15% | 0.00% |
| Completion | 3,000,000 | £0.10 | £0.10 | 50.00% | 3 | 0.15% | 0.00% |
| Senior Mgt | 4,500,000 | £0.10 | £0.15 | 50.00% | 5 | 0.15% | 0.00% |
| Optiva | 1,320,000 | £0.10 | £0.10 | 50.00% | 3 | 0.15% | 0.00% |
| Orana | 175,000 | £0.10 | £0.10 | 50.00% | 3 | 0.15% | 0.00% |
| NED and Advisor | 900,000 | £0.08 | £0.15 | 50.00% | 5 | 0.15% | 0.00% |
TOTAL 13,375,000
* restated – the risk-free rate for all 2021 warrants was incorrectly disclosed as 15% in the 2021 Annual Report. The correct figure (0.15%) was used in the underlying
share-based payment calculations and therefore there is no effect on the 2021 performance or position of the Group and Company.
| Number of | Exer | cise | ||
| Warrants | Warrants | Price | Expiry date | |
| On incorporation | – | – | – | |
| Issued on 25 November 2020 | 5,000,000 | £0.10 | 22 March 2026 | |
| Issued on 25 November 2020 | 7,000,000 | £0.10 | 22 March 2026 | |
| Issued on 17 March 2021 | 1,500,000 | £0.01 | 20 April 2021 | |
| Issued on 17 March 2021 | 480,000 | £0.05 | 22 March 2024 | |
| Issued on 17 March 2021 | 750,000 | £0.05 | 22 March 2026 | |
| Issued on 17 March 2021 | 750,000 | £0.10 | 22 March 2026 | |
| Issued on 17 March 2021 | 10,000,000 | £0.10 | 21 March 2023 | |
| Exercised on 19 April 2021 | (1,500,000) | £0.01 | 20 April 2021 | |
| Issued on 18 August 2021 | 1,500,000 | £0.10 | 22 March 2023 | |
| Issued on 13 October 2021 | 3,000,000 | £0.10 | 21 December 2024 | |
| Issued on 13 October 2021 | 4,500,000 | £0.15 | 21 December 2026 | |
| Issued on 13 October 2021 | 1,320,000 | £0.10 | 21 December 2024 | |
| Issued on 13 October 2021 | 175,000 | £0.10 | 21 December 2024 | |
| At 31 December 2021 | 34,475,000 | £0.105 | ||
| 1 | ||||
| Issued on 28 April 2022 | ||||
| 900,000 | £0.15 | 28 April 2027 | ||
| At 31 December 2022 | 35,375,000 | £0.106 |
1
50% of the warrants vest on 28 April 2023 and the remainder vest on 28 April 2024
The weighted average time to expiry of the warrants as at 31 December 2022 is 3.10 years (2021: 3.05 years).
The expected volatility was calculated using the Exponentially Weighted Moving Average Mode. Due to limited trading
history comparable listed peer company information was used.
Notes to the Financial Statements
continued
72 Roquefort Therapeutics plc
20. Merger Relief Reserve
| Group and Company | £ |
| At 1 January 2021 | – |
| 1 | |
| Acquisition of Lyramid Pty Ltd | |
| 450,000 | |
| At 31 December 2021 | 450,000 |
| 2 | |
| Acquisition of Oncogeni Limited | |
| 3,250,000 | |
| At 31 December 2022 | 3,700,000 |
1
The issue on 21 December 2021 of 5,000,000 new shares relating to the acquisition of Lyramid Pty Ltd. The reserve reflects the difference between the nominal value of shares
at the date of issue of £0.01 and the share price immediately preceding the issue of £0.10 per share. The shares issued formed part of the consideration for the acquisition of
100% of the equity of Lyramid and therefore qualify for merger relief.
2
The issue on 16 September 2022 of 50,000,000 new shares relating to the acquisition of Oncogeni Ltd. The reserve reflects the difference between the nominal value of shares
at the date of issue of £0.01 and the share price immediately preceding the issue of £0.75 per share. The shares issued formed part of the consideration for the acquisition of
100% of the equity of Oncogeni and therefore qualify for merger relief.
21. Financial Instruments and Risk Management
Capital Risk Management
The Group manages its capital to ensure that it will be able to continue as a going concern while maximising the return
to stakeholders. The overall strategy of the Group is to minimise costs and liquidity risk.
The capital structure of the Group consists of equity attributable to equity holders of the Group, comprising issued share
capital, reserves and retained earnings as disclosed in the Statement of Changes of Equity.
The Group is exposed to a number of risks through its normal operations, the most significant of which are interest,
credit, foreign exchange, commodity and liquidity risks. The management of these risks is vested to the Board of
Directors.
The sensitivity has been prepared assuming the liability outstanding was outstanding for the whole period. In all cases
presented, a negative number in profit and loss represents an increase in finance expense / decrease in interest income.
Credit Risk
Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet
its contractual obligations and arises principally from the Group’s receivables from customers. Indicators that there is
no reasonable expectation of recovery include, amongst others, failure to make contractual payments for a period of
greater than 120 days past due.
The carrying amount of financial assets represents the maximum credit exposure.
The principal financial assets of the Group are bank balances. The Group deposits surplus liquid funds with counterparty
banks that have high credit ratings, and the Directors consider the credit risk to be minimal.
The Group’s maximum exposure to credit by class of individual financial instrument is shown in the table below:
| Carrying | Maximum | |
| value at | exposure at | |
| 31 December | 31 December | |
| 2022 | 2022 | |
| £ | £ | |
| Trade receivables | 56,613 | 56,613 |
| Other receivables | 45,124 | 45,124 |
| Cash and cash equivalents | 2,322,974 | 2,322,974 |
| 2,424,741 | 2,424,741 |
Notes to the Financial Statements
continued
Annual Report & Financial Statements 2022 73
Currency Risk
The Group operates in a global market with income and costs possibly arising in a number of currencies and is exposed
to foreign currency risk arising from commercial transactions, translation of assets and liabilities and net investment in
foreign subsidiaries. Exposure to commercial transactions arise from sales or purchases by operating companies in
currencies other than the Group’s functional currency. Currency exposures are reviewed regularly.
The Group has a limited level of exposure to foreign exchange risk through their foreign currency denominated cash
balances and a portion of the Group’s costs being incurred in Australian Dollars. Accordingly, movements in the Sterling
exchange rate against these currencies could have a detrimental effect on the Group’s results and financial condition.
Currency risk is managed by maintaining some cash deposits in currencies other than Sterling.
The table below shows the currency profiles of cash and cash equivalents:
| At 31 December | |
| 2022 | |
| Cash and cash equivalents | £ |
| Sterling | 2,279,240 |
| Australian Dollars | 43,734 |
| 2,322,974 |
Foreign currency sensitivity analysis
As at 31 December 2022, the sensitivity analysis assumes a +/-10% change of the AUD/GBP, exchange rates, which
represents management’s assessment of a reasonably possible change in foreign exchange rates (2021: 10%). The
sensitivity analysis was applied on net loss on the Australian operations and the carrying value of financial assets
and liabilities.
| At 31 December 2022 | At 31 December 2021 | |||
| £ | £ | |||
| +10% weaker | (10%) stronger | +10% weaker | (10%) stronger | |
| Net Loss | ||||
| 1 | ||||
| (34,181) | 34,181 | (1,445) | 1,445 | |
| Carrying value of net assets | (594) | 594 | (167) 167 |
1
10% weaker relates to the Great British Pound weakening against the currency and therefore the Group would incur greater expenditure in its functional currency
2
10% weaker relates to the Great British Pound weakening against the currency and therefore the net liabilities (excluding intercompany borrowings) denominated in AUD will
increase
Liquidity Risk
Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial
liabilities that are settled by delivering cash or another financial asset. The Group’s approach to managing liquidity is to
ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal
and stressed conditions, without incurring unacceptable losses or risking damage to the Group’s reputation.
The Group seeks to manage liquidity risk by regularly reviewing cash flow budgets and forecasts to ensure that sufficient
liquidity is available to meet foreseeable needs and to invest cash assets safely and profitably. The Group deems there
is sufficient liquidity for the foreseeable future. The principal current asset of the business is cash and cash equivalents
and is therefore the principal financial instrument employed by the Group to meet its liquidity requirements. The Board
ensures that the business maintains surplus cash reserves to minimise any liquidity risk.
The financial liabilities of the Group and Company, predominantly trade and other payables, are mostly due within 3
months (2021: 3 months) of the Consolidated Statement of Financial Position date; therefore, the undiscounted amount
payable is the same as their carrying value. Further analysis of the lease commitment is provided in note 23. All other
non-current liabilities are due between 1 to 5 years after the period end. The Group does not have any borrowings or
payables on demand which would increase the risk of the Group not holding sufficient reserves for repayment.
Notes to the Financial Statements
continued
74 Roquefort Therapeutics plc
The Group had cash and cash equivalents at period end as below:
| At 31 December | |
| 2022 | |
| £ | |
| Cash and cash equivalents | 2,322,974 |
| 2,322,974 |
Interest Rate Risk
The Group is exposed to interest rate risk whereby the risk can be a reduction of interest received on cash surpluses
held and an increase in interest on borrowings the Group may have. The maximum exposure to interest rate risk at the
reporting date by class of financial asset was:
| At 31 December | |
| 2022 | |
| £ | |
| Bank balances | 2,322,974 |
| 2,322,974 |
The Group does not currently earn interest on its cash deposits.
22. Financial assets and financial liabilities
| Group | Financial | Financial | |
| Assets | Liabilities | ||
| At amortised | At amortised | ||
| 31 December 2022 | Cost | Cost | Total |
| Financial assets/liabilities | £ | £ | £ |
| Trade and other receivables | 101,737 | – | 101,737 |
| Cash and cash equivalents | 2,322,974 | – | 2,322,974 |
| Trade and other payables | – | (279,668) | (279,668) |
| 2,424,711 | (279,668) | 2,145,043 |
| Company | Financial | Financial | |
| Assets | Liabilities | ||
| At amortised | At amortised | ||
| 31 December 2022 | Cost | Cost | Total |
| Financial assets/liabilities | £ | £ | £ |
| Trade and other receivables | 515,931 | – | 515,931 |
| Cash and cash equivalents | 2,274,478 | – | 2,274,478 |
| Trade and other payables | – | (183,802) | (183,802) |
| 2,790,409 | (183,802) | 2,606,607 |
23. Commitments
| At 31 December | At 31 December | |
| 2022 | 2021 | |
| £ | £ | |
| Committed at the reporting date but not recognised as liabilities, payable: | ||
| Laboratory rental | 37,500 | – |
| Research & Development | 105,655 | – |
Notes to the Financial Statements
continued
Annual Report & Financial Statements 2022 75
Notes to the Financial Statements
continued
24. Contingent Liabilities
There were no contingent liabilities at 31 December 2022 or 31 December 2021. Details of deferred contingent
consideration are disclosed in note 4.2.
25. Related party transactions
There were no related party transactions during the years ended 31 December 2021 and 2022.
26. Post reporting date events
On 20 February 2023 the Company announced that it had signed an exclusive licence and royalty agreement, for the
field of medical diagnostics only, with a leading international diagnostics company, Randox Laboratories Ltd ("Randox"),
in relation to its Midkine antibody portfolio. Randox and Roquefort Therapeutics will now engage in collaborative research
programs to develop new cancer diagnostics that will identify patients treatable with the Company's Midkine
therapeutics. The Group is eligible to receive upfront and potential marketing milestone receipts, as well as royalties on
diagnostics products sold. The Group received from Randox an upfront amount of £200,000 and can earn further
potential milestone receipts of up to £150,000 for marketing approval in certain jurisdictions.
On 8 March 2023 the Company announced that it had successfully developed a new novel platform of anti-cancer
mRNA therapeutics.
27. Ultimate controlling party
As at 31 December 2022, there was no ultimate controlling party of the Company.
Roquefort Therapeutics plc
85 Great Portland Street
First Floor
London W1W 7LT
www.roquefortplc.com
Annual Report & Financial Statements
for the year ended 31 December 2022
Company Registration No. 12819145 (England and Wales)
